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FEASIBILITY OF DAILY ASSESSMENT AND PREDICTORS
OF DAILY QUALITY OF LIFE DURING TREATMENT
FOR LUNG CANCER

by
Laurie E. Steffen

B.A., PSYCHOLOGY, SPANISH
M.S., PSYCHOLOGY
PH.D., PSYCHOLOGY
ABSTRACT
Most lung cancer patients are diagnosed with locally advanced or advance disease, which
makes improving quality of life a critical component of treatment. Empirical research on
daily quality of life in lung cancer is lacking, despite a growing focus on patient-reported
outcomes in oncology. The goal of this study was to determine the feasibility of daily
assessment of quality of life and to identify predictors of daily quality of life in lung
cancer patients undergoing treatment. It was hypothesized that clinical characteristics
such as treatment type would predict feasibility. It was hypothesized that patients with
higher hope would report better quality of life and that daily hope would predict daily
quality of life. Fifty-six of 62 patients who were approached enrolled, of which 50 (89%)
completed a baseline questionnaire and sufficient daily assessments to be included in
analysis. Diary patients (58% female, 78% non-small cell, 66% metastatic disease,
average age = 68.66, SD = 8.78) completed an average of 20.45 (SD = 1.62, range = 1526) days. Clinical characteristics and daily survey administration method did not predict
the number of days completed. Patients with higher levels of hope reported higher social
and role functioning (estimate = 3.37, SE = 0.90, 95% CI = 1.60, 5.14) and higher
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palliative wellbeing (estimate = 0.88, SE = 0.24, 95% CI = 0.40, 1.35). On days where
patients reported higher hope, they reported higher social and role functioning (estimate =
2.36, SE = 0.70, 95% CI = 1.00, 3.73), better physical functioning (estimate = 2.27, SE =
0.81, 95% CI = 0.68, 3.87), and higher palliative wellbeing (estimate = 0.91, SE = 0.13,
95% CI = 0.66, 1.16). Daily hope appeared to attenuate the impact of treatment days on
social and role functioning (estimate = 3.33, SE = 1.25, 95% CI = 0.88, 5.77). Daily hope
did not predict quality of life in next-day models. Daily hope was not predicted by lung
cancer symptoms. Results suggest that daily assessment of quality of life in lung cancer
patients is feasible and that hope-based interventions may improve their quality of life.
Keywords: Lung cancer, quality of life, daily diary, hope, stigma
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Introduction
In 2016, over 221,000 new lung cancer cases are expected in the U.S., along with
158,080 lung cancer deaths (American Cancer Society; ACS, 2016). The number of
deaths caused by lung cancer is comparable to the number of deaths caused by breast,
colon, pancreas, and prostate cancer combined (ACS). Overall one-year survival for lung
cancer is 44%, whereas overall five-year survival for lung cancer is 17% (ACS). For
patients diagnosed with localized disease, five-year survival rate is 54% compared to a
rate of less than 4% for those with distant metastases. Only 15% of lung cancers are
diagnosed at a localized stage; the majority of lung cancer patients will die from the
disease.
In addition to a bleak future for survival, lung cancer patients can experience a
host of physical symptoms from disease such as cough, fatigue, and dyspnea and
neurological symptoms (Corner, Hopkinson, Fitzsimmons, Barclay, & Muers, 2005;
Hamilton, Peters, Round, & Sharp, 2005; van Meerbeeck, Fennell, & De Ruysscher,
2011). There is some evidence that patients prioritize symptom management over
lengthening survival time (Silvestri, Pritchard, & Welch, 1998). Treatment
(chemotherapy or chemoradiotherapy) is usually the best way to manage physical
symptoms and prolong life (Davidoff, Tang, Seal, & Edelman, 2010; Peters et al., 2012),
but it comes with risks and side effects that can be difficult for patients to tolerate.
Maximizing patient functioning and overall quality of life is a critical component
of treatment for lung cancer (Smith et al., 2012). Population studies suggest that lung
cancer patients suffer higher degrees of decline in mental health, social functioning, and
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overall well-being compared to other cancer patients (Reeve et al., 2009) and a larger
disease burden over time (Deshields, Potter, Olsen, & Liu, 2014). Although lung cancer
presents an important opportunity for quality of life research, this area of research is
limited by inadequate assessment of both quality of life and disease-related variables.
Studies that do assess both quality of life and disease factors often conclude that disease
severity can be a risk factor for distress (Montazeri, Gillis, & McEwen, 1998), which
although potentially helpful for identifying subgroups that are most likely to need
services, does not provide enough direction into what should be targeted behaviorally to
improve quality of life. Improving quality of life research in lung cancer patients depends
on implementing study designs that will answer questions as to the relationship between
disease factors, symptoms, and individual responses to the challenging nature of lung
cancer. Once the relationships between disease, symptoms, behaviors, and quality of life
are characterized, clinical interventions can be developed to improve quality of life.
Assessment of Quality of Life in Lung Cancer: More than Symptoms
Measures of quality of life that are included in clinical trials mostly focus on
physical symptoms. Frequently, the emotional wellbeing and functional scales of quality
of life measures are omitted (Zikos et al., 2014). Such a finding is not surprising given
that most quality of life reports come from medical providers overseeing clinical trials in
which the priority is disease response and physical symptom severity. However, physical
symptoms are only one aspect of quality of life and provide little information into the
patients’ daily experiences, social relationships, and leisure activities that also reflect
quality of life (Montazori et al., 1998).
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Many symptoms are distressing to patients because of their impact on aspects of
daily life—not because the symptoms themselves are inherently distressing (Ellis, 2012).
Qualitative research suggests that symptoms such as cough and shortness of breath may
deter socialization because of patient embarrassment about symptoms (Molassiotis,
Lowe, Blackhall, & Lorigan, 2011) and interfere with daily activities (Chan, Richardson,
& Richardson, 2005). Symptoms may trigger thoughts related to fear of death, lost sense
of self in illness, and stigma of disease (Ellis, 2012). The impact of stigma in lung cancer
on patient quality of life can be substantial and contribute to social isolation and
depression (Berterö, Vanhanen, & Appelin, 2008; Cataldo, Jahan, & Pongquan, 2012;
Chapple, Ziebland, & McPherson, 2004; Gonzalez & Jacobsen, 2012; LoConte, ElseQuest, Eickhoff, Hyde, & Schiller, 2008). Assessing quality of life in lung cancer
requires attention to the relationships that physical symptoms have with other aspects of
patient wellbeing.
A Framework for Quality of Life in Cancer
The theme underlying research on quality of life in this area is that cancer can
alter several domains including social relationships, occupation, physical ability, belief
systems, and overall sense of life direction (Brennan, 2001; Folkman & Greer, 2000;
Stanton, 2006). Clinical manifestations can include depression, anxiety, social isolation,
withdrawal, and relationship problems. People who are able to maintain or enhance life
during cancer may be less prone to clinical manifestations such as depression, but they
are probably not acting with the intention of avoiding the development of depression or
anxiety—they are doing something more. One possibility is that they are continuing to
engage in aspects of life that are rewarding to them or identifying new ones. Planning,
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setting goals, re-evaluating values, and changing priorities are all thought to be important
to wellbeing by helping patients identify meaningful and feasible actions to take to
improve quality of life (Schroevers, Kraaij, & Garnefski, 2011; Schroevers, Kraaij, &
Garnefski, 2008).
A measure developed by Snyder and colleagues (1991) has potential to capture
some aspects of this response to cancer. The measure describes a person’s intentional
action toward a desired and potentially achievable outcome, which Snyder called “hope.”
Hope is defined as agency (goal-directed energy—essentially attending to potential goals
to pursue) and pathways (planning to meet goals). Hope has been associated less fatigue,
depression, pain, and coughing among lung cancer patients (Berendes et al., 2010). It is
also related to positive affect, which is associated with adaptive social functioning, less
role restriction, and less severe bodily pain among lung cancer patients (Hirsch, Floyd, &
Duberstein, 2012). Therefore, cross-sectional work suggests a correlation between hope
and functioning. It remains to be seen, however, how hope and functioning influence one
another longitudinally. Hope may be an adaptive response that aids quality of life or it
may merely reflect lower symptom burden, which would limit its clinical utility.
An Appropriate Design for Quality of Life Research in Lung Cancer
Capturing the variability in lung cancer symptoms, their impact on daily
functioning, and helpful responses to the daily challenges of the disease requires a
longitudinal design. Much of the research to date on lung cancer patients has been crosssectional or has relied on assessment points every few months. In addition to recall bias,
those between-person designs (i.e., designs that are cross-sectional or use statistical
methods that fail to model variance occurring at the level of individual differences and
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within-person behavior) are not sensitive to the day-to-day fluctuations in symptoms and
functioning that are most relevant to patients’ quality of life. Daily assessment
methodology provides the opportunity to examine processes that are not accessible
through between-person designs (Bolger, Davis, & Rafaeli, 2003; Tennen, Affleck,
Armeli, & Carney, 2000) and obtains patient reports of symptoms and functioning close
to the time of their occurrence, thereby minimizing retrospective bias (Laurenceau &
Bolger, 2005; Tennen et al., 2000). The temporal proximity of data combined with the
use of people as their own statistical control (i.e., each person’s mean is considered in
modeling within-person changes) strengthens the ability to make directional inference.
By modeling variance within and across individuals, daily assessment designs can
determine whether symptoms such as fatigue are explained by a change in a person’s
behavior, are mostly accounted for by lung cancer stage or subtype, or may be impacted
by certain behaviors for people with specific disease characteristics. Such questions are
worth exploring given the potentially different strains that lung cancer may place on a
person based on subtype, stage, and treatment. Non-small-cell lung cancer (NSCLC; 85%
of all lung cancers) patients with locally advanced disease and small-cell lung cancer
(SCLC; ~15% of all lung cancers) patients with limited disease undergo treatments (i.e.,
chemoradiotherapy or sequential treatment) with high potential for side effects. However,
the possibility of a cure, although small (i.e., only occurring in 20-25% of NSCLC with
locally advanced disease; Siegel, Miller, & Jemal, 2016) may help patients endure
treatment. For patients with advanced NSCLC or extensive SCLC, treatment (i.e.,
chemotherapy) may be less grueling, but rarely cures disease. A patient with SCLC may
respond quite well initially to treatment, as 80-95% of patients with limited disease and
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60-80% of patients with extensive disease show an overall response (Hanna & Einhorn,
2002; Stupp, Monnerat, Turrisi III, Perry, & Leyvraz, 2004). However, SCLC tends to
rapidly progress and has a shorter survival time than NSCLC. Disease characteristics and
treatment factors can therefore be expected to contribute to differences in psychological
response and daily functioning and can be explicitly modeled in daily assessment studies.
Despite its potential for illuminating processes underlying patient quality of life,
few published studies have used daily assessment methodology with lung cancer patients;
feasibility concerns have likely been prohibitive. Lung cancer tends to metastasize to the
brain, especially in extensive SCLC (Beckles, Spiro, Colice, & Rudd, 2003). However,
many patients have brain metastases but are cognitively asymptomatic (Seute, Leffers,
ten Velde, & Twijnstra, 2008) and disease in the brain can respond to chemotherapy or
chemotherapy followed by radiation (van Meerbeeck et al., 2011). Presence of brain
metastases alone should not prevent lung cancer patients from participating in quality of
life research. In fact, several studies suggest that lung cancer patients can engage in daily
diary studies. A 12-week daily symptom diary study of 135 (103 of whom were in late
stage disease) lung cancer patients receiving chemotherapy reported compliance rates of
71% at three weeks (Brown et al., 2005). A 12-week study of weekly symptom
assessments among stage III and IV lung cancer patients showed an 86% adherence rate
at 3 weeks (Yount et al., 2013). Although these studies have limited their scope to
symptoms alone or an overall rating of quality of life (Bezjak et al., 2002), they have
demonstrated daily symptom variation (e.g., pain and mood; Lasheen, Walsh, Hauser,
Gutgsell, & Karafa, 2009; fatigue; Brown et al., 2005).
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Whether expanding quality of life assessment beyond symptom severity decreases
adherence is an empirical question. Missing data is common in quality of life research
among people with advanced disease (Donaldson & Moinpour, 2005; Earle, 2004). Daily
assessment may offer a way to circumvent the problems of low power for detecting
effects among this population (Earle, 2004) and is aligned with the goal of identifying
ways to improve patients’ day-to-day lives.
Current Study
This study used daily assessment methodology to research quality of life among
lung cancer patients [NSCLC stages IIIA-IV (i.e., locally advanced to metastatic); limited
or extensive SCLC] undergoing treatment for lung cancer. Use of an intensive
longitudinal design provided tests of the relationships between psychological factors,
daily symptom severity, and functioning while controlling for concomitant medical and
disease factors that could account for variance in patient quality of life.
Aims and Hypotheses
The first aim of this study was to establish the feasibility of daily quality of life
assessment in patients receiving medical treatment for lung cancer and to identify
potential patient characteristics that contribute to feasibility. Feasibility was quantified
by: 1) the percentage of patients who consented vs. declined participation; 2) the
percentage of patients consented who completed the baseline questionnaire only vs.
consented with baseline data and daily diary data; 3) the average percentage of missing
diary data; and 4) the number of people who required an alternative to online daily
assessment (e.g., paper assessments). Those with a higher performance status (i.e., more
impaired physically), lower baseline reports of quality of life, and who were undergoing
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chemoradiotherapy were hypothesized to have lower daily completion rates. Those who
completed the daily surveys online were hypothesized to have higher response rates than
those who completed them on paper.
The second aim of this study was to provide preliminary tests of the effects of
psychological risk and protective factors on patient daily quality of life when taking into
account concomitant medical factors. Controlling for baseline psychosocial functioning
(e.g., depression and quality of life), performance status, and patient report of the
previous day’s quality of life, higher daily perceived lung cancer stigma was
hypothesized to predict lower daily functioning and quality of life. Controlling for
baseline psychosocial functioning (e.g., depression, quality of life), performance status,
and patient report of the previous day’s quality of life, daily hope was hypothesized to
predict higher daily functioning and quality of life. A secondary aim of this study was to
estimate effect sizes to inform future research on patient characteristics that may
moderate these relationships, such as disease stage, its corresponding treatment, and
performance status.
Method
Power and Sample Size Calculations
Power analysis in multilevel modeling reflects both level-1 and level-2 effect
sizes, sample size (level-1 and level-2), the intraclass correlation (ICC; the amount of
dependency in the data), and alpha level. Sample size requirements should be calculated
based on the highest level (level-2) in the design (Hox, 2010). For studying cross-level
(i.e. level-1 and level-2) interactions, Hox suggests a sample of 50 level-2 units and 20
level-1 observations. The highest level (level-2) in this project was the individual. Level-
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1 variables were within-person changes day to day. The power analysis used to estimate
the necessary sample size for this project was based on a similarly structured data (i.e.,
days nested within individuals), but involved emergency responders as participants (84
people; average number of days = 18.5, SD = 2.97 days). The analysis was conducted
through MLPOWSIM (Browne, Golalizadeh, & Parker, 2009) and controlled for level-2
variables (e.g., depression and optimism) and level-1 variables (e.g., coping, pain). Based
on the emergency responder sample, 48 people and 19 days of data were needed for a
power of .78 for level-1 hope (hope ICC = .83;  = .05, b = .133 for predicting positive
affect, 95% CI = .054 to .210). However, the effect sizes of these variables were
unknown in lung cancer patients and adherence to daily survey completion among this
population was expected to range from 70-80% (Brown et al. 2005, Yount et al., 2013).
Given anticipated rates of missing data and dropout, enrolling 65 people and requesting
21 days of data was expected to yield a sample of 50 people with at least 15 days of data.
Level-2 comparisons based on disease stage or subtype were not expected to be powered
to reject the null hypothesis and were exploratory aims.
Participants
Eligibility criteria included: (a) Histologically or cytologically documented nonsmall cell lung cancer (NSCLC) stage IIIa, IIIb, or IV (7th edition staging;
adenocarcinoma, large cell, squamous, or mixture of these types) or limited or extensive
small cell lung cancer (SCLC); (b) 21 years of age or older; (c) Eastern Cooperative
Oncology Group performance status 0-2 (0 = fully active, able to carry on all pre-disease
performance without restriction; 1 = restricted in physically strenuous activity but
ambulatory and able to carry out work of a light or sedentary nature; 2 = ambulatory and
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capable of all self-care, but unable to carry out any work activities; up and about more
than 50% of waking hours); (d) no concurrent malignancy or unstable brain metastases
(defined as those with midline shift, inadequately controlled seizures or requiring
escalating steroid doses); (e) undergoing treatment for lung cancer specific to stage IIIa,
IIIb, or IV NSCLC or limited or extensive small cell SCLC; (f) patient could speak and
read English; (g) could provide informed consent; and had (h) no active psychoses or
impairment that would preclude compliance with the study.
Procedure
Recruitment Site.
UNM Cancer Center. Recruitment began in April 2014 and ended in September
2015. Participants were recruited through the University of New Mexico Cancer Center
(UNMCC). A number of recruitment strategies were used within the cancer center
including: recruitment cards provided to oncologists to distribute to eligible patients,
fliers posted in the oncology clinic waiting area and infusion floor, and pre-screening
patients for eligibility through the clinic’s weekly schedule. Patients who were eligible
based on the pre-screening were approached after their appointments with oncologists or
at their chemotherapy appointments. A Health Insurance Portability and Accountability
Act waiver was granted by the IRB for recruitment purposes with corresponding approval
for the pre-screening procedure described. Patients provided written informed consent.
The UNM Health Sciences Center Institutional Review Board and the New Mexico
Cancer Care Alliance approved this study.
Assessment
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Patients completed an initial questionnaire on a computer or on paper. Patients
could choose to complete daily diaries online through Opinio, on paper, or, via telephone
if needed. Patients who chose to complete surveys online were emailed a link for the
daily survey each day at their preferred time of day to complete the survey. If patients
had not completed the survey within 5 hours of their assessment window, an automatic
reminder was sent. Patients were encouraged to report the previous day’s diary before
entering the current day if they missed a day. Time of completion and date were captured
through the online survey system. Patients were required to enter the date their responses
corresponded to, which helped assure correct sequence of dairies if a patient missed a
day.
Patients who completed daily diaries on paper were given 21 daily diaries that
they were to date with the time of day completed and minutes taken to complete. They
were provided with a self-addressed, postage-paid return envelope. Initially, patients who
completed paper diaries were given a flat-rate envelope and therefore returned all 21
diaries at once. Research staff checked in weekly with patients to assure adherence and
patients had the option of receiving a reminder to do the daily survey as often as often as
they felt they needed or wanted it. Halfway through the study’s data collection period,
patients who completed paper diaries were given envelopes to mail each week, with the
intention of improving validity of daily assessment. Whether patients mailed batches of
surveys and how daily surveys were administered was tracked.
Participant Remuneration
Participants were paid $30 for completing the initial questionnaire, $3 for each daily
entry (up to $63 possible), $4 for each week they completed (up to $12 possible), and $6
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for completing all 21 days. The daily portion of the study compensated up to $81. Total
remuneration could be $111. Participants received payment in the form of gift cards to
either Target or Wal-Mart.
Measures Administered
Level 2 (i.e. Baseline Individual) Variables (Appendix A).
Demographic Information. Participant sex, education, relationship status, age,
ethnicity, race, income, treatment type, time since diagnosis, and smoking status and
history was assessed.
Depression and Anxiety. The Hospital Anxiety and Depression Scale (HADS;
Zigmond & Snaith, 1983) was used to assess anxiety and depression symptoms. It
contains 14 items (seven specific to anxiety and seven specific to depression). Each
question was answered on a four-point Likert-type scale (1 = not at all to 4 = very often).
The HADS has been normed in cancer patients (Bjelland, Dahl, Haug, & Neckelmann,
2002). Internal consistency was good in this sample (depression  = .82; anxiety  =
.86).
Neuroticism. The neuroticism items from the Big Five Personality Inventory
(Benet-Martínez & John, 1998) was used to assess people’s tendency to experience
negative affect. Seven items assessed neuroticism with statements that were rated in
terms of agreement from 1 = strongly disagree to 5 = strongly agree. Internal consistency
in the sample was acceptable ( = .70)
Optimism. The optimism items from the Life Orientation Scale-Revised (LOT-R;
Scheier, Carver, & Bridges, 1994) was used to assess a person’s tendency to experience
positive affect. Six items assessed optimism with statements rated in terms of agreement
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from 1 = strongly disagree to 5 = strongly agree. Internal consistency in this sample was
good ( = .77).
Physical Symptoms and Functioning. The Functional Assessment of Cancer
Therapy (FACT) version four (Cella et al., 1995) was used to assess quality of life and
functioning. The FACT-L (FACT-Lung) contains four general (FACT-G; physical wellbeing, social/family well-being, emotional well-being, and functional well-being) and one
lung cancer-specific subscale. The lung cancer subscale is comprised of seven items and
assesses symptoms commonly reported among patients (e.g., shortness of breath). Scores
on the lung cancer subscale can range from 0 to 28. Scores on the FACT-G (the four
general subscales of FACT-L) can range from 0 to 108. The Trial Outcome Index (TOI)
is indicated by the physical wellbeing, functional wellbeing, and lung cancer subscales.
Scores can range from 0 to 84. The FACT-L total score is derived by summing five
subscales. Scores can range from 0 to 136. On all scoring iterations, higher scores
indicate better quality of life or fewer symptoms.
The FACT-L has been used as a secondary endpoint in large medical treatment
studies to measure quality of life (e.g., ECOG Study 5592; Cella et al., 2002). A study
evaluating FACT scores between two clinic visits 15 days apart showed that scores
declined. Intraclass correlations between the two visits ranged from .78 (social/family
well-being) to .96 (FACT-L TOI; Juliana, Jardim, Fernandes, Jamnik, & Santoro, 2010).
Mean values for the FACT-G have ranged from 65.9 to 84.1 in clinical trials with cancer
patients. Mean values for the lung cancer subscale have ranged from 16.2 to 20.5 in lung
cancer patients (Juliana et al., 2010). Internal consistency in the current sample was good
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(Physical Wellbeing  = .87, Social Wellbeing  = .84, Emotional Wellbeing  = .83,
Functional Wellbeing  = .85).
The European Organisation for Research and Treatment of Cancer (EORTC)
Quality of Life Questionnaire in Cancer-30 (QLQ-C30) uses nine multi-item scales: five
functional (physical, role, cognitive, emotional, and social functioning); three symptom
scales (fatigue, pain, nausea/vomiting), and a global health status/quality of life scale.
The scale was originally tested in lung cancer patients (Aaronson et al., 1993). The 30item scale norms for stage III-IV lung cancer suggest means of 54.7 (SD = 23.8) for
global health status/quality of life, 65.9 (SD = 25.6) for physical functioning, 55.5 (SD =
34.5) for role functioning, 67.3 (SD = 24.1) for emotional functioning, 81.6 (SD = 22.7)
for cognitive functioning, and 69.8 (SD = 30.3) for social functioning (EORTC Quality
of Life Group; Scott, et al, 2001). Internal consistency in the current sample was good
(Emotional functioning  = .87, Physical functioning  = .82, Role functioning  = .90,
Cognitive functioning  = .69, Social functioning  = .79).
Hope. The Dispositional Hope Scale (Snyder et al., 1991) assessed trait hope
through eight items such as “I can think of many ways to get the things in life that are
most important to me” on a scale of 1 = definitely false to 4 = definitely true. Internal
consistency in the current sample was good ( = .77).
Lung Cancer Stigma. Lung cancer stigma was assessed using the Cataldo Lung
Cancer Stigma Scale (Cataldo, Slaughter, Jahan, Pongquan, & Hwang, 2011). Thirty-one
items assessed stigma and shame (11 items; e.g. “I feel guilty because I have lung
cancer”), social isolation (10 items; e.g. “I have lost friends by telling them that I have
lung cancer”), discrimination (5 items; “People with lung cancer are treated like
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outcasts”) and smoking (5 items; e.g. “Lung cancer is viewed as a self-inflicted disease”)
through a 4-point Likert-type scale of strongly disagree to strongly agree. Scores can
range from 46-184, with higher scores indicating more stigma. In a sample of 190 lung
cancer patients in all stages of disease, the average score was 120.31 (SD = 30.36;
Cataldo et al., 2012). Internal consistency in the current sample was excellent ( = .94).
Level-1 (i.e. Daily) Variables (Appendix B).
Patients were prompted to think about the past 24 hours when responding to
questions in the following domains.
Level-1 (Daily) Predictor Variables
Treatment Day. Treatment day was a binary variable (0 = no) (1= yes) indicating
whether or not someone had chemotherapy or radiation that day.
Physical Symptoms. Seven items from the FACT-L (e.g. “Were you short of
breath?”, “Did you have pain?”, “Did you lack appetite?”, “How much did you cough?”,
“Did you feel weak?”, “Did you feel nauseated?, and “Were you tired?”) assessed daily
physical symptoms on a scale of 1 = not at all to 4 = very much. Items were rescaled 0 to
3 and averaged. Internal consistency was good ( = 0.83, day 1).
Daily Hope. Daily hope was assessed using four items from State Hope Scale
(Snyder et al., 1996): “At the present time, I am trying to pursue my personal goals and
plans” (agency), “I can think of many ways to reach my current goals” (agency), “There
are ways around any problem that I am facing now” (pathways), and “I can think of many
ways to reach my current goals” (pathways). Items were responded to on a scale of 1
(definitely false) to 8 (definitely true). Items were rescaled 0 to 7 and averaged. Internal
consistency was good ( = 0.83, day 1).
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Lung Cancer Stigma. Five items (e.g. “Some people act as though it is my fault
that I have lung cancer”, “I feel guilty because I have lung cancer”, “I feel set apart,
isolated from the rest of the world”, “Having lung cancer makes me feel like I’m a bad
person”, “Some people who know have grown more distant”) from the Cataldo Lung
Cancer Stigma Scale (Cataldo et al., 2011) were used to assess daily experience of lung
cancer stigma, shame, social isolation and discrimination. A 4-point Likert-type scale was
used (1 = strongly disagree to 4 = strongly agree). Items were rescaled 0 to 3 and
averaged. Internal consistency was good ( = 0.82, day 1).
Level-1 (Daily) Dependent Variables
Social/Role Functioning. Role functioning was assessed with two items from the
EORTQ-QLQ-30 (“Were you limited in pursuing your hobbies or other leisure time
activities?”, “Were you limited in pursuing your work or other daily activities?”). Items
were responded to on a scale of 1 = not at all to 4 = very much. Following the scoring
procedures from the EORTC-QLQ-30 (v.3) manual, role functioning was transformed
linearly to have a range of 0-100, with higher scores reflecting higher role functioning.
Internal consistency was acceptable ( = .75, day 1). Social functioning was assessed
with two items from the EORTC-QLC-30 (“Has your physical condition or medical
treatment interfered with your family life today?”, and “Has your physical condition or
medical treatment interfered with your social life today?”). Items were responded to on a
scale of 1 = not at all to 4 = very much. Following the scoring procedures from the
EORTC-QLQ-30 (v.3) manual, interference was transformed linearly to have a range of
0-100, with higher scores reflecting better social functioning. Internal consistency was
acceptable ( = .60, day 1). Social and role functioning subscales were averaged to yield
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an index of daily functioning. Following the scoring procedures from the EORTC-QLQ30 (v.3) manual, social/role functioning was transformed linearly to have a range of 0100, with higher scores reflecting better functioning. Internal consistency for the
combined subscales was good ( = .86, day 1).
Palliative Well-Being. Palliative well-being was assessed using 7 items from the
Additional Concerns Scale of the FACIT-Palliative Care Scale (“I feel useful”, “I feel
independent”, “I feel like a burden to my family”, “I feel that my family appreciates me”,
“I maintain contact with my friends”, “I make each day count”, “I am able to openly
discuss my concerns with the people closest to me”) and one item from the Functional
Well-Being Scale (“I am able to enjoy life”). Items were responded to on a 0 (not at all)
to 4 (very much) scale. In accordance with the FACIT manual, palliative well-being was
calculated if participants answered at least four FACIT questions. Items were summed,
multiplied by 8, and then divided by the number of valid items. Internal consistency was
adequate ( = 0.79, day 1).
Physical Functioning. Physical functioning was assessed with the one item scale
of physical functioning from the EORTC-QLQ-30 (“Did you need to stay in a bed or a
chair during the day today?”) responded to on a scale of 1 = not at all to 4 = very much.
Following the scoring procedures from the EORTC-QLQ-30 (v.3) manual, physical
functioning was transformed linearly to have a range of 0-100, with higher scores
reflecting better physical functioning.
Statistical Analyses
Data were analyzed using SPSS (v. 21) and, for HLM, MPlus (v.7; Muthén &
Muthén, 2012). Adherence to the daily diary was calculated as the number of completed
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questionnaires divided by the expected questionnaires (i.e., number of patients x 21
days). Predictors of the number of days completed in the diary were analyzed using
multiple regression in the full sample (i.e., including patients who completed 0 days of
the diary). Descriptive statistics were used to summarize predictor variables. Percentages
of patients reporting moderate/severe symptoms of cough, shortness of breath, pain,
weakness, nausea, fatigue, staying in bed, and being bothered by side effects were also
plotted across the 21 days of the diary.
The repeated (daily) data was nested within an individual. Hierarchical Linear
Modeling (HLM) was used to address the nested structure (i.e., dependence) of the data
and estimate both the Level-1 (daily) and Level-2 (individual) variance. HLM
accommodates missing data through the use of full information maximum likelihood
estimation, which maximizes the probability of the data and is recommended in quality of
life research in lung cancer (Hox, 2010) (Donaldson & Moinpour, 2005). The Level-1
data included daily ratings symptom severity, functioning, medical treatment events,
stigma, and hope. The Level-2 data included demographic information (e.g. age, cancer
type and stage, treatment type), baseline quality of life, personality (e.g. neuroticism,
optimism), and depression and anxiety.
To separate sources of variance, Level 1 (i.e., daily) predictor variables were
person-mean centered so that each person’s daily predictor variable represented
deviations from his or her overall average on that daily predictor variable. As such,
regression slopes for Level-1 predictors represent pooled within-person relationships
between the predictor and the dependent variable. A person’s average on a daily predictor
variable was included in the model as a Level-2 predictor. The regression slope for those
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Level-2 predictors represents the between-person relationship between the average score
of the predictor and the average score of the dependent variable. For Level-2 predictors
assessed at baseline, if a clinically meaningful score was available for centering (e.g., a
score of “8” representing a likely “case” of depression), each person’s score was centered
on it to make the intercept more interpretable (e.g., in the case of depression, a score of
“0” would be a clinical case). Level-2 predictors without a clinically meaningful center
value were grand mean centered so that each person’s score represented their deviation
from the overall sample mean on that predictor.
Analysis of Fixed Effect Hypotheses (Specific Aim 2)
The unconditional model was estimated first to partition variance into within and
between-person variability. Next, time was included as a predictor variable to help assess
for reactivity to monitoring (Barta, Tennen, & Litt, 2013). To assess for whether
administration method (i.e., online vs. paper) made a difference in responses,
administration method was added as a predictor. Finally, the rest of the pre-specified
model was estimated. Variables that were theorized to be important disease variables to
control for were maintained in all models, regardless of statistical significance; however,
Level-2 control predictors such as depression, anxiety, neuroticism, and optimism were
removed if they did not change the significance of predictors that were the focus of
hypotheses. A reduced form equation for a final model is below. The equation below
shows the “next day” model (i.e., t + 1).
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𝑠𝑜𝑐𝑖𝑎𝑙𝑓𝑢𝑛𝑐𝑡𝑡+1𝑖
= 𝛾00 + 𝛾01 𝐴𝑛𝑥𝑖𝑒𝑡𝑦𝑖 + 𝛾02 𝑎𝑔𝑒𝑔𝑐𝑖 + 𝛾03 𝑡𝑥𝑡𝑦𝑝𝑒 + 𝛾04 ℎ𝑜𝑝𝑒𝑝𝑚𝑖 + 𝛾05 𝑠𝑡𝑖𝑔𝑚𝑎𝑝𝑚𝑖
+ 𝜇0𝑖 + 𝛾06 𝑠𝑦𝑚𝑝𝑡𝑜𝑚𝑠𝑝𝑚𝑖 + 𝛽10 𝑑𝑎𝑦𝑠𝑑𝑥𝑡𝑖 + 𝛽20 𝑡𝑥𝑑𝑎𝑦𝑡𝑖 + 𝛽30 ℎ𝑜𝑝𝑒𝑝𝑐𝑡𝑖
+ 𝛽40 𝑠𝑡𝑖𝑔𝑚𝑎𝑝𝑐𝑡𝑖 + 𝛽50 𝑠𝑦𝑚𝑝𝑡𝑜𝑚𝑠𝑝𝑐𝑡𝑖 + 𝛽60 𝑠𝑜𝑐𝑖𝑎𝑙𝑓𝑢𝑛𝑐𝑡𝑡𝑖 + 𝛽70 𝑝𝑜𝑠𝑎𝑓𝑓𝑒𝑐𝑡𝑝𝑐𝑡𝑖
+ 𝛽80 𝑛𝑒𝑔𝑎𝑓𝑓𝑒𝑐𝑡𝑝𝑐𝑡𝑖 + 𝛽90 ℎ𝑜𝑝𝑒𝑝𝑐𝑋𝑡𝑥𝑑𝑎𝑦𝑡𝑖 + 𝑒𝑖
Results
Descriptive statistics are shown in Table 1. The sample (N = 56) had more
females (n = 32; 57.1%) than males (n = 24; 42.9%). Average age was 68.29 years (SD =
9.47 yrs). The majority of the sample was non-Hispanic white (n = 46; 82.1%). Thirtythree people (58.9%) were married or living with their romantic partner. Average number
of years of education was 13.54 (SD = 2.73 yrs). Most patients had non-small cell lung
cancer (n = 42; 75.0%), advanced disease (stage IV NSC = 66.7%; extensive SC =
78.6%), and were receiving either chemotherapy (n = 30; 53.6%) or chemoradiotherapy
(n = 18; 32.1%). Thirteen (23.2%) had brain metastases. Most had an ECOG performance
status of 1 (n = 31; 55.4%). Demographics for the final analyzed sample (n = 50) were
similar (Table 1). Descriptive statistics for clinical scales from the sample appear in Table
2. About one-third of the sample met criteria for likely clinical depression and anxiety.
Lung cancer stigma was relatively low compared to previous research (Cataldo et al.,
2012). Functioning and lung cancer symptom scales were similar to previous studies
(Scott et al., 2001).
Feasibility
Recruitment and retention data are shown in Figure 1. Two patients responded to
the recruitment fliers in waiting rooms, two were referred directly from a physician, and
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the remaining patients were identified through the pre-screening procedure. Sixty-two
patients were approached about the study, of which 56 (90.3%) consented. Of those who
declined (n = 6; 9.7%), two said they were too busy with work, one said it sounded too
tedious, one said the next 21 days were too uncertain, one was in too much pain, and one
expressed concerns about a clause about limits of privacy and law enforcement in the
consent form.
Of the 56 who consented, 52 (92.9%) completed at least one day of the diary.
Reasons for drop out after baseline included: “busy schedule” (n = 1), death (n = 1),
hospitalized for one week or more (n = 1), and “too much to handle right now” (n = 1).
Fifty of the 52 people who participated in the diary were retained for daily diary analysis.
Two people (3.8%) were excluded for analysis because they completed only one or four
days. Reasons for drop out included being hospitalized for one week or more (n = 1) or
the study being “too much to handle” (n = 1). The average number of days completed in
the full sample was 18.46 (SD = 6.33; range = 0-26). The average number of days in the
full sample with cap of 21 days total was 18.21 (SD = 6.23; range = 0 – 21). Of the 1,176
potential daily diaries (62 people x 21 days), 1,052 (89.5%) were completed (excluding 8
days completed beyond the 21 day window). The average number of days completed in
the sample retained for daily diary analysis was 20.45 (SD = 1.62, range = 15-26). The
average number of days completed in the sample retained for daily diary analysis with
cap of 21 days total was 20.30 (SD = 1.34, range = 15-21). Of the 1,050 potential daily
diaries (50 people x 21 days), 1,042 (99.2%) were completed (excluding 8 days
completed beyond the 21 days). Forty-three (86%) of the daily diary sample completed
20 days or more.
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In the full sample (N = 56), most patients (n = 34; 60.7%) completed the daily
surveys on paper; 19 (33.9%) completed surveys online; 3 (5.4%) completed surveys on
the telephone. Of those who completed surveys on paper, 11 (32.4%) mailed surveys to
the investigator in weekly batches. For analysis concerning daily administration method,
the three telephone-administered diary sets were combined with those who completed the
surveys online because both groups received daily contact. In the sample retained for
daily diary analysis, 56% (n = 28) completed questionnaires on paper, of which 10 (20%)
mailed questionnaires in batches. In the full sample (N = 56), the average time per day to
complete a diary was 10.85 minutes (SD = 7.07 minutes; range 3 – 60 minutes). In the
sample retained for daily diary analysis (n = 50), the average time per day to complete a
diary was 10.78 minutes (SD = 6.88; range = 3 – 45 minutes). Figure 2 shows the average
number of minutes it took the sample to complete the diary per day across the diary.
Missing dependent variable data for the daily diary was under 5%.
Contrary to Hypothesis 1, physician-rated performance status, baseline quality of
life, treatment type (concurrent chemoradiotherapy vs. chemotherapy), and daily survey
administration method did not predict number of days completed for the diary, although
there was a trend for people completing the surveys on paper to complete fewer days (B =
-3.19, SE = 1.84, 95% CI = -3.94, 3.40; Table 3).
Daily Quality of Life
Descriptive statistics for daily quality of life variables appear in Table 4. Most
people reported relatively little restriction to the bed or chair during the day, low
impairment in work and daily activities, and low interference with family and social life.
Coughing, shortness of breath, fatigue, pain, and weakness were the most severe daily
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physical symptoms of lung cancer. Figure 3 shows the percentages of patients who
endorsed “quite a bit” or “very much” on symptoms and being bothered by symptoms
across days 1-21 of the diary. Fatigue was consistently at moderate to severe levels.
There were 307 days on which patients reported receiving lung cancer treatment,
representing 30.8% of diary days. Cancer-related setbacks were rare, occurring only 38
times (3.6% of diary days). Correlations between study variables appear in Table 5.
Daily Social/Role Functioning. Approximately 66.8% of the variance in daily
social and role functioning resided at level 2, implying that people had different average
levels of functioning and that there was a lot of homogeneity on daily social and role
functioning for a person. The grand mean of functioning was 68.09 (SE = 3.19). The
within person variance for ratings of functioning was 247.70 and the between person
variance was 497.36. There did not appear to be reactivity to the diary, as day of the diary
did not predict daily functioning when added as a sole predictor (estimate = 0.12, SE =
0.08, 95% CI = -.03 to 0.28) and within and between person variance remained similar
(247.51 and 498.10, respectively).
Results for predictors of daily social/role functioning appear in Table 6. Age, days
since diagnosis, and treatment type did not predict daily functioning. Daily social and
role functioning was predicted by differences in mean levels of hope (estimate = 5.06, SE
= 1.37, 95% CI = 2.37, 7.75), baseline anxiety (estimate = -1.22, SE = 0.48, 95% CI = 2.16, -0.29), and physical symptoms of lung cancer (estimate = -21.66, SE = 3.85, 95%
CI = -29.22, -14.11). On days where patients reported higher hope (estimate = 2.36, SE =
0.70; 95% CI = 1.00, 3.73) and more positive affect (estimate = 8.31, SE = 0.95, 95% CI
= 6.45, 10.17), they reported better functioning, whereas on days where they reported
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more stigma (estimate = -3.64, SE = 1.60, 95% CI = -6.78, -0.51) and more physical
symptoms (estimate = -17.37, SE = 2.63, 95% CI = -22.52, -12.22), they reported lower
functioning. Physical symptoms appeared to vary randomly across people (estimate =
138.45, SE = 58.76, 95% CI = 23.29, 253.61). Treatment day and daily hope interacted
such that on days where patients experienced higher hope, they reported less of a
negative effect of going to cancer treatment (estimate = 3.33, SE = 1.25, 95% CI = 0.88,
5.77; Figure 3).
Next Day Social/Role Functioning
To better understand the influence of hope and stigma on daily functioning, the
same predictors were added to a model that predicted next day functioning while
controlling for current day level of functioning (see equation above). A non-significant
interaction between daily hope and treatment day (estimate = 2.36, SE = 1.52, p = .121)
was removed from the final equation. The resulting model appears in Table 7. Age, days
since diagnosis, and treatment type did not predict next day functioning. Consistent with
the same day model, next day social and role functioning was predicted by differences in
mean levels of physical symptoms (estimate = -13.91, SE = 2.68, 95% CI = -19.17, 8.66), baseline anxiety (estimate = -0.72, SE = 0.30, 95% CI = -1.32, -0.13), and hope
(estimate = 3.37, SE = 0.90, 95% CI = 1.60, 5.14). Unlike the same day model, daily
positive affect and stigma did not predict next day social and role functioning; daily hope
trended toward higher next day functioning (estimate = 1.29, SE = 0.73, 95% CI = -0.14,
2.72) and daily physical symptoms predicted lower next day functioning (estimate = 7.71, SE = 2.68, 95% CI = -12.96, -2.45).
Daily Physical Functioning
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Approximately 64% of the variance in daily physical functioning occurred at level
2, implying that people had different average levels of functioning and that there was a
lot of homogeneity within a person regarding how much they stayed in bed or a chair
during day. The grand mean of physical functioning was 65.50 (SE = 3.86). The within
person variance for ratings of physical functioning was 403.51 and the between person
variance was 725.90. There did not appear to be reactivity to the diary, as day was not a
significant predictor when added to the null model as a sole predictor (estimate = 0.12,
SE = 0.10, 95% CI = -0.08 to 0.34) and both within and between person variance
estimates remained similar with the addition of day as a predictor (400.20 and 727.05,
respectively).
There was a trend for an interaction between daily hope and treatment day
(estimate = 3.08, SE = 1.71, p = .072) such that higher daily hope appeared to buffer
against the negative impact of treatment days on physical functioning. Results appear in
Table 8. The interaction term was removed. People who were undergoing concurrent
chemoradiotherapy (estimate = -10.11, SE = 4.95, 95% CI = -19.81, -0.41) and older
(estimate = -0.56, SE = 0.26, 95% CI = -1.08, -0.04) and who reported more depression
(estimate = -1.78, SE = 0.67, 95% CI = -3.10, -0.46) and physical symptoms (estimate = 32.06, SE = 4.83, 95% CI = -41.52, -22.60) reported lower physical functioning. On days
where people experienced higher hope (estimate = 2.27, SE = 0.81; 95% CI = 0.68, 3.87)
and more positive affect (estimate = 8.64, SE = 1.31; 95% CI = 6.08, 11.19), they
reported better physical functioning, whereas on days where they reported more
symptoms (estimate = -26.11, SE = 3.67, 95% CI = -33.30, -18.92), they reported worse

26
physical functioning. Lung cancer symptoms appeared to vary randomly across people
(estimate = 282.59, SE = 104.57, 95% CI = 77.62, 487.55).
Next Day Physical Functioning
The same model used for predicting same day physical functioning was used to
predict next day physical functioning, while controlling for current day physical
functioning. Results appear in Table 9. Consistent with the same day model, people who
were older, had higher levels of depression, and more physical symptoms reported lower
next day functioning. Treatment type trended toward people receiving concurrent
chemoradiotherapy reporting lower next day functioning (estimate = -7.39, SE = 3.88,
95% CI = -15.00, 0.21). Daily functioning was related to next day functioning (estimate =
0.27, SE = 0.05, 95% CI = 0.18, 0.36). Daily hope and positive affect were not related to
next day functioning, whereas daily physical symptoms remained a significant predictor
of next day functioning (estimate = -12.16, SE = 3.58, 95% CI = -19.14, -5.12).
Palliative Well-being
Approximately 75% of the variance in palliative quality of life resided at level 2,
implying that people had different mean levels of palliative quality of life and there was a
lot of homogeneity within a person on this measure. The grand mean of palliative quality
of life was 21.20 (SE = 0.76). The within person variance for ratings of palliative quality
of life was 9.61 (SE = 0.44, 95% CI = 8.79 to 10.50) and the between person variance
was 28.50 (SE = 5.80, 95% CI = 19.13 to 42.46). There did not appear to be reactivity to
the diary, as day was not a significant predictor when added to the null model (estimate =
-0.01, SE = 0.02, 95% CI = -0.05 to 0.02) and both within and between person variance
estimates remained essentially the same (9.64 and 28.51, respectively).
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Results appear in Table 10. Age, treatment type, and days since diagnosis did not
predict daily palliative wellbeing. Palliative wellbeing was predicted by differences in
mean levels of depression (estimate = -0.38, SE = 0.15, 95% CI = -0.66, -0.09), hope
(estimate = 1.54, SE = 0.37, 95% CI = 0.81, 2.26), and stigma (estimate = -3.37, SE =
1.20, 95% CI = -5.73, -1.01). On days where people reported higher levels of hope
(estimate = 0.91, SE = 0.13, 95% CI = 0.66, 1.16) and positive affect (estimate = 2.05, SE
= 0.20, 95% CI = 1.66, 2.45) they reported higher palliative wellbeing, whereas on days
where they reported more stigma (estimate = -0.80, SE = 0.34, 95% CI = -1.46, -0.13)
and had treatment (estimate = -0.45, SE = 0.22, 95% CI = -0.89, -0.02), they reported
lower palliative wellbeing. Lung cancer symptoms appeared to vary randomly across
people (estimate = 4.97, SE = 2.20, 95% CI = 0.66, 9.27).
Next Day Palliative Wellbeing
The same model used for predicting same day palliative wellbeing was tested for
next day palliative wellbeing except that current day wellbeing was included as a control
variable. Results are shown in Table 11. As in the same day model, age, days since
diagnosis, treatment type, and lung cancer symptoms did not predict next day wellbeing.
Palliative wellbeing was predicted by differences in mean levels of hope (estimate = 0.88,
SE = 0.24, 95% CI = 0.40, 1.35), and stigma (estimate = -1.71, SE = 0.71, 95% CI = 3.10, -0.32). On days where people reported higher levels of positive affect (estimate =
0.49, SE = 0.24, 95% CI = 0.03, 0.96) they reported higher next day palliative wellbeing.
Directionality: Hope as a Predictor or Dependent Variable?
Hope was evaluated as a dependent variable of daily functioning, physical
functioning, and palliative wellbeing to further clarify the relationships between study
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variables. Daily functioning, physical functioning, and palliative wellbeing were first
examined one at a time with the other predictor variables in same and next day models;
however, they were ultimately entered into the same predictive model as results did not
change when the other two predictor variables were excluded. Differences in mean
social/role functioning and palliative wellbeing predicted daily hope (estimate = 0.03, SE
= 0.01, 95% CI = 0.0001 to 0.05, 0.14, SE = 0.04, 95% CI = 0.06, 0.22, respectively;
Table 12). On days where people reported higher social/role functioning (estimate = .01,
SE = 0.002, 95% CI = 0.004, 0.01) and higher palliative wellbeing (estimate = 0.05, SE =
0.01, 95% CI = 0.04, 0.07) they reported higher daily hope.
The same model used for predicting same day hope was tested for next day hope
except that current day hope was included as a control variable. Results are shown in
Table 13. Differences in mean palliative wellbeing (estimate = 0.08, SE = 0.03, 95% CI =
0.03, 0.13) and higher daily palliative wellbeing (estimate = 0.03, SE = 0.01, 95% CI =
0.01, 0.04) predicted next day hope. There was a trend for differences in mean social/role
functioning predicting higher next day hope (estimate = 0.01, SE = 0.01, 95% CI = 0.002, 0.03). Notably, lung cancer symptoms—neither daily nor mean levels—did not
predict daily same day or next day hope.
Discussion
The goal of this study was to determine the feasibility of daily assessment of
quality of life in lung cancer patients and to identify predictors of daily quality of life.
This was accomplished using a 21-day intensive longitudinal design. Based on the
consent rate, retention rate, adherence rate, and limited missing data, daily assessment
appears to be feasible within this population. Both chemotherapy and chemoradiotherapy
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patients were able to complete the daily diaries, as were patients with brain metastases or
who had received whole brain radiotherapy prior to starting the study. The majority of the
patients in this sample had late stage (i.e., stage IV non-small cell or extensive small cell)
lung cancer, indicating that they can be included in quality of life studies of this nature.
Although the daily diary questionnaire had 60 questions, average time to complete a diary
each day was around 11 minutes, which suggests that daily diaries may be a quick way to
assess various domains of quality of life. More patients completed the diaries on paper
than online, perhaps reflecting the age of the sample and the fact that many people in the
state sampled do not have internet in their homes. It did not appear that those with more
physical impairment at the start of the diary completed fewer days, although small
comparison groups limit this conclusion.
One of the goals of this study was to understand the within person variance of
day-to-day quality of life after accounting for individual differences. Time since
diagnosis did not predict daily quality of life. Lung cancer treatment type, which reflects
disease stage, was also not a predictor of daily quality of life with the exception of daily
physical functioning. Those who were undergoing concurrent chemoradiotherapy
reported more time in bed or a chair during the day. This finding is congruent with the
toxicity of chemoradiotherapy.
Daily lung cancer symptoms were clearly important to assess, as they predicted
worse daily social/role functioning and physical functioning. However, daily lung cancer
symptoms did not predict palliative well-being, which was surprising as some of the
items on the palliative well-being scale seemed like they would fluctuate based on
symptoms (e.g., “I feel independent” or “I feel like a burden to my family.”) The fact that
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daily lung cancer symptoms did not predict palliative wellbeing suggests that high lung
cancer symptom burden does not preclude a quality of life intervention: patients are still
able to stay in touch with friends, feel useful, or enjoy daily life when experiencing
difficult symptoms. Those activities matter to quality of life in lung cancer patients
(Montazeri et al., 1998; Schroevers et al., 2011; Schroevers et al., 2008).
Lung cancer stigma was an inconsistent predictor of daily quality of life. Higher
averages of lung cancer stigma were associated with lower palliative wellbeing, even
when controlling for a previous report of palliative wellbeing. Daily experiences of lung
cancer stigma appeared to have a deleterious effect on social/role functioning and
palliative wellbeing even when controlling for negative affect. This finding is consistent
with the existing cross-sectional literature on lung cancer stigma and quality of life
(Cataldo & Brodsky, 2013; Cataldo et al., 2012). Most of the patients in the sample had a
history of smoking; however, all but seven reported that they were not smoking at the
time of the study. The small sample size of current smokers in the study precluded
meaningful comparisons of the effect of smoking status on lung cancer stigma and
quality of life. However, pack years were examined in an exploratory analysis and did not
predict daily quality of life or interact with the level of stigma patients reported in the
daily diary (results not shown). A larger sample of current smokers would be needed to
understand the effect of smoking on daily quality of life in the context of lung cancer
stigma. Existing evidence suggests that lung cancer stigma is experienced regardless of
smoking history (Cataldo et al., 2012).
Daily positive affect was a clear predictor of palliative wellbeing and
demonstrated same-day relationships to social/role functioning and physical functioning.
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This finding is not surprising, as positive affect has correlated with quality of life in other
studies (Hirsch et al., 2012). For the purpose of informing intervention, it was important
to determine whether or not daily hope added anything to predicting quality of life
beyond positive affect. People with higher hope reported higher palliative wellbeing and
social/role functioning, regardless of their previous day’s report of quality of life. Results
suggest that daily hope may positively impact daily quality of life, as it demonstrated
same-day relationships with social/role functioning, physical functioning, and palliative
well-being. Higher daily hope also appeared to be useful on days when patients had lung
cancer treatments, reducing the negative impact that treatment had on social/role
functioning. The interaction between daily hope and treatment day is intriguing, as
treatment is a major part of life for patients and can vary from 1-6 hours of chemotherapy
infusion to 15 minutes of radiation. Keeping patients active and engaged with aspects of
life that they find rewarding is an important quality of life goal and supports patients
through medical treatment of their disease (Arrieta et al., 2013; Greer, Pirl, Park, Lynch,
& Temel, 2008; Lithoxopoulou et al., 2014; Montazeri, Milroy, Hole, McEwen, & Gillis,
2001; Lemonnier et al., 2014). Patient hope may facilitate that patient care goal.
A logical question about hope is whether or not it is should be conceptualized as a
predictor of or a result of better quality of life. Longitudinal models provided some
insight into directionality and seemed to suggest that daily hope was not a strong
predictor once the previous day’s quality of life had been taken into account. However,
the relationship between daily hope and treatment days was primarily of interest for same
day relationships, as the question was what helped people on days when they were
receiving lung cancer treatment. Daily hope trended toward higher next day social/role
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functioning. Hope was examined as a dependent variable to determine whether daily
levels of hope were a byproduct of fewer symptoms or better functioning. Daily palliative
wellbeing did influence daily hope, even when controlling for previous levels of daily
hope, whereas daily lung cancer symptoms and physical functioning did not influence
daily hope. Thus, hope does not seem to reflect higher or lower levels of lung cancer
symptoms.
Results on the relationship between daily quality of life and hope are not
incongruent with the construct of hope. Given that the construct of hope used was
focused on personal goals, plans, and identifying ways around problems, it makes sense
that better functioning and wellbeing would promote higher daily hope. When people do
their work or hobbies, engage with their social life, and try to “make each day count,”
they are more likely to meet their personal goals, work towards fulfilling their plans, and
stay focused on what matters to them. Engaging in hope behavior should promote
functioning, and functioning should promote more hope behavior (Snyder, 2002). Given
that higher average social/role functioning correlated with higher average hope, people
who come into treatment with better functioning are likely to engage more easily in hope
behavior. Patients with lower functioning at the start of treatment are likely to have lower
hope—these are the patients who might benefit the most from a hope intervention.
Other researchers have suggested the potential benefit of a hope intervention for
lung cancer patients (Berendes et al., 2010). Previously recommended components of a
hope intervention have included: discussing patient understanding of their diagnosis, goal
identification and prioritizing goals based on importance, identifying short-term and
long-term goals that are realistic, identifying steps to take towards goals, and helping
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patients monitor their own progress in working towards goals (Berendes et al., 2010). The
behavioral targets of a hope intervention could be tailored to a person’s specific situation
and values as long as the clinician’s organizing conceptualization is that lung cancer
reduces quality of life when people disengage from activities they can still realistically
carry out. The goal of a hope-based intervention, therefore, would be to promote the
maintenance of realistic and valued directions in daily life while a patient faces new
disease challenges and physical decline, which makes physicians an important part of
hope interventions.
Communication with physicians is associated with patient outcomes (Taenzer et
al., 2000). Most patients want to know about their diagnosis and have opportunities to ask
questions (Hagerty et al., 2004), yet many lung cancer patients have unmet physician
communication needs (Nelson et al., 2011). Providers can facilitate hope by starting
conversations with patients early on about what activities are realistic and continuing to
revisit patient life goals during treatment. One way to help understand patient goals may
be to ask what would be important to do or what would be most important to the patient if
she or he did not improve (Clayton et al., 2005). Another way would be to ask patients
what they expect in the future with their illness (Roenn & Gunten, 2003). Without some
sense of what might be possible from a medical standpoint, patients may have difficulty
setting personal goals throughout illness, give up activities unnecessarily, or try to do too
much. The ways in which patients pursue valued daily life directions should change
throughout disease course (Sachs et al., 2013; Benzein, Norberg, & Saveman, 2001),
which makes involving caregivers important, as caregivers are vital to cancer patients
throughout disease progression. Caregivers themselves may become an appropriate focus
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of intervention as disease progresses, thereby providing an indirect intervention for the
patient by supporting the caregiver. Caregiver interventions are already established
(Porter et al., 2011; Chih et al., 2013; Gustafson et al., 2013), although more intensive
study on the relationship between caregiver intervention and patient functioning is
needed in this population.
In summary, if hope is thought of as identifying available quality of life actions
throughout illness, it should be useful throughout the course of disease and be influenced
by direct intervention with the patient, provider behavior, and involvement with
caregivers. Existing hope interventions provide starting point for designing a hope-based
intervention for quality of life in lung cancer, but more work needs to be done to
determine how to manipulate hope within the context of changing disease and patient
abilities.
Limitations
Although to our knowledge this is the first intensive longitudinal study of quality
of life among this patient population, results and conclusions are limited by a number of
factors. First, the level-2 sample size made it difficult to detect between person
differences based on lung cancer subtype or stage. Although some of the variability that
might exist based on disease characteristics was likely reflected in treatment type, larger
comparison groups might identify different needs for small cell vs. non-small cell
patients or those with earlier vs. metastatic disease. Second, over half of the patients in
this sample chose to complete the daily diaries on paper and less than half of those who
did the diary on paper were asked to mail them in using weekly batches. Without the time
stamp of online administration, it is impossible to know how precisely some of the
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patients adhered to the daily diary schedule. However, investigators did check in with
patients to see how they were doing completing the diaries. Similarly, because adherence
was anticipated to be a problem with this population, every effort was made to make it as
simple as possible, including letting patients identify their preferred time of day to
complete the diary instead of forcing all patients to complete at the end of the day.
Therefore, some patients were reflecting on 24 hours from a time in the morning, whereas
others were reflecting on 24 hours from a time in the evening. A uniform time window
would increase ability to draw conclusions about what patients were reflecting on when
answering questions on the diary.
Third, assessment of reactivity to the diary was not built into the study design. It
is possible that patients self-monitored (i.e., became more aware of their affect ratings or
physical activity level, for example) during the diary and that this influenced their daily
ratings. Response shift can occur with daily diary studies such that patients establish new
levels of what anchors mean to them (e.g., “5” becomes a “3” as they reflect on previous
ratings). This concern is reduced somewhat by the nature of the daily diary. Specifically,
the number of items, assessment of several domains instead of one behavior, and mixed
valence of behaviors/experiences measured (e.g., staying in bed vs. enjoying life) reduces
the likelihood of reactivity to the diary (Barta, Tennen, & Litt, 2013). However, patients
who had access to their daily diaries were at greater risk for reactivity, despite
administration method not appearing to influence daily ratings. Fourth, although
completion rates of the daily diary were high, it is likely that patients missed diaries on
days when they were feeling the worst. This was addressed as best as possible by
encouraging patients to enter a missed day prior to their current day’s report; however,
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that procedure introduced increased possibility of retrospective bias. Finally, patients
were receiving medical oncology care from a variety of providers, which meant that there
was not a uniform treatment for patients based on disease subtype or stage, making stage
and subtype less useful predictors than they might be were patients receiving care from
the same clinic provider.
Conclusion
Results of this study demonstrate the feasibility of assessing daily quality of life
in late stage lung cancer patients, including those with disease in the brain. Given the
prevalence of late stage lung cancer and the limited number of quality of life studies
among the population to date, the feasibility data is encouraging. A number of predictors
of daily quality of life were identified through this design, including hope and lung
cancer stigma, which suggests that they may be useful intervention targets. Future studies
may benefit from asking patients to identify specific activities that they did each day as a
way to track what types of behaviors reflect or contribute to better quality of life. Prior to
implementing a hope intervention in this population, it may be useful to try to manipulate
hope by asking a subset of patients to list actionable goals for the day (e.g., call a friend,
write down my questions for my oncologist, sit outside, etc.), or identify ways to increase
the likelihood of it being a valued day (e.g., ask for help, remind self of reasons for doing
something, etc.). Involving a caregiver in a dyadic diary study would also yield helpful
information as to hope behaviors that promote quality of life. Finally, testing whether or
not giving feedback to medical providers about the patients’ weekly diaries prior to
patient upcoming appointments might help identify whether or not diaries could improve
patient care. At least one study has found a very brief assessment of quality of life to be
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related to positive clinical outcomes, with minimal provider burden (Hubbard, Grothey,
McWilliams, Buckner, & Sloan, 2014). Building a larger diary study from the results of
this study might help to identify a set of quality of life items that are important and vary
day-to-day for patients.

38

APPENDIX A: BASELINE QUESTIONNAIRE
Date:
Time Started:

ID: ____________
REVISED 2/8/15

A. Demographic Information & Information about your cancer experience
1. Sex

____ Female

____ Male

2. Years of Education (including grades 1-12; HS degree = 12 years; 4 year
college degree = 16 years) ____
3. Current marital/relationship status (check one)
_____ Never married
_____ Married

_____ Divorced

_____ Separated

_____Widowed

_____Living with romantic partner

4. Age______________
5. Are you Hispanic or Latino/a?
____ yes

___no

6. What ethnic or racial groups do you identify with (check all that apply)?
_____White

_____ Asian or Pacific Islander

_____ Black

_____ American Indian or Alaskan Native

_____ Other (Specify:
__________________________________________________________)
7. What is your annual income (you or you and your spouse/partner)?
______________
8. Are you currently receiving any of these treatments for you cancer?
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___ radiation
___ surgery
___ chemotherapy
____combination radiation & chemo
____ combination radiation & surgery
____ combination surgery & chemo
____ combination surgery, chemo, & radiation
9. When were you diagnosed with lung cancer?
date: __________ or approximate number of days ago _________
10. Do you currently smoke? yes
no
a. If yes, how many cigarettes a day do you smoke?
b. How many years have you smoked?
c. If no, have you ever smoked?
yes
no
d. How many cigarettes a day did you smoke?
e. How many years did you smoke?
11. My expectation is that treatment will cure my lung cancer.
0
1
2
3
Not at all true

slightly true

somewhat true

mostly true

4
very true

Please circle one number to indicate your response to each of the
following questions.
not at
a
somewhat a lot a great
all
little
deal
To what extent do you consider
1
2
3
4
5
yourself a religious person?
To what extent is religion
1
2
3
4
5
involved in understanding or
dealing with stressful situations
in your life?
To what extent is religion
1
2
3
4
5
helpful in understanding or
dealing with stressful situations
in your life?
To what extent do you consider
1
2
3
4
5
yourself a spiritual person?
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To what extent is spirituality
involved in understanding or
dealing with stressful situations
in your life?

1

2

3

4

5

To what extent is spirituality
helpful in understanding or
dealing with stressful situations
in your life?

1

2

3

4

5

Not at all

a little bit

quite a
bit

very
much

1. Do you have any trouble
doing strenuous activities,
like carrying a heavy
shopping bag or a suitcase?

1

2

3

4

2. Do you have any trouble
taking a long walk?

1

2

3

4

3. Do you have any trouble
taking a short walk outside
of the house?
4. Do you need to stay in bed
or a chair during the day?

1

2

3

4

1

2

3

4

5. Do you need help with
eating, dressing, washing
yourself or using the toilet?

1

2

3

4

Not at all

a little bit

quite a
bit

very
much

1

2

3

4

EORTC. Quality of Life

During the past week:
6. Were you limited in doing
either your work or other
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daily activities?
7. Were you limited in
pursuing your hobbies or
other leisure time activities?
8. Were you short of breath?

1

2

3

4

1

2

3

4

9. Have you had pain?

1

2

3

4

10. Did you need to rest?

1

2

3

4

11. Have you had trouble
sleeping?

1

2

3

4

Not at all

a little bit

12. Have you felt weak?

1

2

quite a
bit

13. Have you lacked
appetite?

1

14. Have you felt nauseated?

very
much

3

4

2

3

4

1

2

3

4

15. Have you vomited?

1

2

3

4

16. Have you been
constipated?

1

2

3

4

17. Have you had diarrhea?

1

2

3

4

18. Were you tired?

1

2

3

4

19. Did pain interfere with
your daily activities?

1

2

3

4

20. Have you had difficulty
in concentrating on things,
like reading a newspaper or
watching television?
21. Did you feel tense?

1

2

3

4

1

2

3

4

22. Did you worry?

1

2

3

4
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23. Did you feel irritable?

1

2

3

4

24. Did you feel depressed?

1

2

3

4

25. Have you had difficulty
remembering things?
26. Has your physical
condition or medical
treatment interfered with
your family life?
27. Has your physical
condition or medical
treatment interfered with
your social activities?
28. Has your physical
condition or medical
treatment caused you
financial difficulties?

1

2

3

4

1

2

3

4

1

2

3

4

1

2

3

4

For the following questions please circle the number between 1 and 7
that
best applies to you.
29. How would you rate your overall health during the past week?
1

2

3

4

5

6

7
Very poor
Excellent
30. How would you rate your overall quality of life during the past week?
1

2

7
Very poor
Excellent
FACT-L

3

4

5

6
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Below is a list of statements that other people with your illness have said are
important. Please circle or mark one number per line to indicate your
response as it applies to the past 7 days.
PHYSICAL WELL-BEING

Not at
all

A
little
bit

Somewhat

Quite Very
a bit much

0
1
2
GP1 I have a lack of energy ........................................................

3

4

0
1
2
GP2 I have nausea.......................................................................

3

4

GP3 Because of my physical
condition, I have trouble meeting
0
1
2
the needs of my family .......................................................

3

4

0
1
2
GP4 I have pain ...........................................................................

3

4

0
1
2
GP5 I am bothered by side effects of
treatment .............................................................................

3

4

0
1
2
GP6 I feel ill ................................................................................

3

4

0
1
2
GP7 I am forced to spend time in bed ........................................

3

4

SOCIAL/FAMILY WELLBEING

Not at
all

A
little
bit

Somewhat

Quite Very
a bit much

0
1
2
GS1 I feel close to my friends ....................................................

3

4

0
1
2
GS2 I get emotional support from my
family ..................................................................................

3

4

0
1
2
GS3 I get support from my friends .............................................

3

4

0
1
2
GS4 My family has accepted my
illness ..................................................................................

3

4

3

4

GS5 I am satisfied with family
communication about my illness ........................................
0
1
2
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GS6 I feel close to my partner (or the
person who is my main support).........................................
0
1
2

3

4

Regardless of your current level
of sexual activity, please answer
the following question. If you
prefer not to answer it, please
mark this box
and go to the
next section.
0
1
2
GS7 I am satisfied with my sex life ............................................

3

4

Q1

Please circle or mark one number per line to indicate your response as it
applies to the past 7 days.

Quite
a bit

Very
much

0
1
2
GE1 I feel sad .............................................................................

3

4

0
1
2
GE2 I am satisfied with how I am
coping with my illness ........................................................

3

4

0
1
2
GE3 I am losing hope in the fight
against my illness ...............................................................

3

4

0
1
2
GE4 I feel nervous ......................................................................

3

4

0
1
2
GE5 I worry about dying ............................................................

3

4

0
1
2
GE6 I worry that my condition will
get worse .............................................................................

3

4

Quite
a bit

Very
much

EMOTIONAL WELL-BEING

FUNCTIONAL WELLBEING

Not at
all

Not at
all

A
little
bit

A
little
bit

Somewhat

Somewhat
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GF1

I am able to work (include work
0
1
2
at home) ..............................................................................

3

4

GF2

My work (include work at home)
0
1
2
is fulfilling ..........................................................................

3

4

GF3

I am able to enjoy life .........................................................
0
1
2

3

4

GF4

I have accepted my illness ..................................................
0
1
2

3

4

GF5

I am sleeping well...............................................................
0
1
2

3

4

GF6

I am enjoying the things I
0
1
2
usually do for fun ...............................................................

3

4

GF7

I am content with the quality of
0
1
2
my life right now ................................................................

3

4

Please circle or mark one number per line to indicate your response as it
applies to the past 7 days.

ADDITIONAL CONCERNS

Not at A little Someall
bit
what

Quite
a bit

Very
much

B1

I have been short of breath .........................................
0
1

2

3

4

C2

I am losing weight ......................................................
0
1

2

3

4

L1

My thinking is clear ....................................................
0
1

2

3

4

L2

I have been coughing ..................................................
0
1

2

3

4

B5

I am bothered by hair loss ..........................................
0
1

2

3

4
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C6

I have a good appetite .................................................
0
1

2

3

4

L3

I feel tightness in my chest .........................................
0
1

2

3

4

L4

Breathing is easy for me .............................................
0
1

2

3

4

Q3

Have you ever smoked?
No ___ Yes ___ If yes:

L5

I regret my smoking ...................................................
0
1

2

3

4

strongly
disagree
(1)
1

2
2

3
3

strongly
agree
(4)
4

2. I work hard to keep my lung cancer
a secret.

1

2

3

4

3. Having lung cancer makes me feel
like I’m a bad person.

1

2

3

4

4. I’m very careful whom I tell I have
lung cancer.

1

2

3

4

5. I feel I’m not as good as others
because I have lung cancer.

1

2

3

4

6. Having lung cancer makes me feel
unclean.

1

2

3

4

7. I feel set apart, isolated from the rest
of the world.

1

2

3

4

1. I feel guilty because I have lung
cancer.
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8. My lung cancer diagnosis was
delayed because I put off going to the
doctor.

1

2

3

4

9. Some told me lung cancer is what I
deserved for smoking.

1

2

3

4

10. My lung cancer diagnosis was
delayed because my healthcare
provider did not take my “smoker’s
cough” seriously.

1

2

3

4

11. Smokers could be refused
treatment for lung cancer.

1

2

3

4

12. I have lost friends by telling them I
have lung cancer.

1

2

3

4

strongly
disagree
(1)

2

3

strongly
agree
(4)

14. People have physically backed
away from me.

1

2

3

4

15. People I care about stopped calling
after learning that I have lung cancer.
16. People seem afraid of me because I
have lung cancer.

1

2

3

4

1

2

3

4

17. People avoid touching me if they
know I have lung cancer.

1

2

3

4

18. People avoid you because lung
cancer is associated with death.

1

2

3

4

19. Some people who know have

1

2

3

4

13. I stopped socializing with some
because of their reactions.
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grown more distant.
20. I was hurt how people reacted to
learning I have lung cancer.

1

2

3

4

21. I worry about people
discriminating against me.

1

2

3

4

22. People with lung cancer are treated
like outcasts.

1

2

3

4

23. Most people believe a person with
lung cancer is dirty.

1

2

3

4

24. Most are uncomfortable around
someone with lung cancer.

1

2

3

4

25. I worry that people may judge me
when they learn I have lung cancer.

1

2

3

4

26. People with lung cancer lose jobs
when employers learn.

1

2

3

4

27. Lung cancer is viewed as a selfinflicted disease.

strongly
disagree
(1)

2

3

strongly
agree
(4)

1

2

3

4

29. Others assume that a patient’s lung
cancer was caused by smoking, even if
he or she had stopped smoking years
ago.

1

2

3

4

30. Some people act as though it is my
fault that I have lung cancer.

1

2

3

4

31. Healthcare providers don’t take

1

2

3

4

28. Others assume that a patient’s lung
cancer was caused by smoking, even if
he or she never smoked.
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“smoker’s cough” seriously.
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Section B: Personal Characteristics
Instructions: Please read each statement and decide how much you disagree or agree
with it. Circle one number for each statement using the following scale.

Do you see yourself as

strongly

someone who….

disagree

1. Is relaxed, handles

disagree

neutral

agree

strongly
agree

1

2

3

4

5

2. Can be moody

1

2

3

4

5

3. Is depressed, blue

1

2

3

4

5

4. Can be tense

1

2

3

4

5

5. Worries a lot

1

2

3

4

5

6. Remains calm in tense

1

2

3

4

5

7. Is emotionally stable,

strongly

disagree

neutral

agree

strongly

not easily upset

disagree

2

3

4

agree

stress well

situations

1

5

8. Gets nervous easily

1

2

3

4

5

9. In uncertain time, I

1

2

3

4

5

1

2

3

4

5

1

2

3

4

5

1

2

3

4

5

1

2

3

4

5

usually expect the best
10. If something can go
wrong for me, it will
11. I’m always optimistic
about my future
12. I hardly ever expect
things to go my way
13. I rarely count on good
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things happening to me
14. Overall, I expect more

1

2

3

4

5

good things to happen to
me than bad
Please select the number that best describes you.
definitely mostly
false
false
1. I can think of many ways to
1
2
get out of a jam
2. I energetically pursue my
1
2
goals
3. There are lots of ways around
any problem
4. I meet the goals that I set for
myself
5. I can think of many ways to
get the things in life that are most
important to me
6. I’ve been pretty successful in
life
7. Even when others get
discouraged, I know I can find a
way to solve a problem
8. My past experiences have
prepared me well for my future
9. As I encounter difficulties, I
will not get stuck
10. I see potential when I think of
what is ahead
11. I am focused on what matters
to me as I go through what I am
facing now

mostly definitely
true
true
3
4
3

4

1

2

3

4

1

2

3

4

1

2

3

4

definitely
false
1
1

mostly
false
2
2

1

2

3

4

1

2

3

4

1

2

3

4

1

2

3

4

mostly definitely
true
true
3
4
3
4
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12. I am focusing on what matters
to me and it shows

1

2

3

4

13. I see many ways of pursuing
what is most important to me now

1

2

3

4

14. I am keeping in mind what
matters most to me

1

2

3

4

15. Even though I may not be
able to meet a goal I have set for
myself, I am doing what I can

1

2

3

4

16. Daily life is not about the
likelihood of reaching my goals,
but rather about the process of
working towards something
17. Because it makes my life
better, it is important for me to
pursue what may be possible for
me even if it is difficult

1

2

3

4

1

2

3

4
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Think about the past 2 weeks and check one blank for each statement.
1. I felt tense or wound up.
____ Most of the time
____ A lot of the time
____ From time to time, occasionally
____ Not at all

8. I felt as if I was slowed down.
____ Nearly all the time
____ Very often
____ Sometimes
____ Not at all

2. I enjoyed the things I used to enjoy.

9. I got a sort of frightened feeling
like butterflies in my stomach

____
____
____
____

Definitely as much
Not quite as much
Only a little
Hardly at all

3. I got a sort of frightened feeling as if
something awful was about to happen.
____ Very definitely and quite badly
____ Yes, but not too badly
____ A little, but it didn’t worry me
____ Not at all
4. I could laugh and see the funny side of things.
____
____
____
____

As much as I always could
Not quite so much now
Definitely not so much now
Not at all

5. Worrying thoughts went through my mind.
____
____
____
____

A great deal of the time
A lot of the time
From time to time but not too often.
Only occasionally

____ Not at all
____ Occasionally
____ Quite often
____ Very often
10. I have lost interest in my
appearance.
___ Definitely
____ I don’t take so much care as I
should
____ I may not take quite as much
care
____ I take just as much care as ever
11. I felt restless as if I had to be on
the move.
____ Very much indeed
____ Quite a lot
____ Not very much
____ Not at all
12. I looked forward with enjoyment
to things.
____ As much as I ever did
____ Rather less than I used to
____ Definitely less than I used to
____ Hardly at all

6. I felt cheerful.
____ Not at all
____ Not often
____ Sometimes
____ Most of the time

13. I got sudden feelings of panic.
____ Very much indeed
____ Quite a lot
____ Not very much
____ Not at all

7. I could sit at ease and feel relaxed.
program.
____ Definitely

14. I could enjoy a book/radio/TV
____ Often
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____ Usually
____ Not often
____ Not at all

____ Sometimes
____ Not often
____ Very seldom

“If I have to stop pursuing an important goal in my life…”
almost
never
true (1)
1. It’s easy for me to reduce my
1
2
3
4
effort toward the goal.

almost
always
true (5)
5

2. I find it difficult to stop
trying to achieve the goal.

1

2

3

4

5

3. I stay committed to the goal
for a long time; I can’t let it go.

1

2

3

4

5

4. It’s easy for me to stop
thinking about the goal and let
it go.

1

2

3

4

5

5. I think about other new goals
to pursue.

1

2

3

4

5

6. I seek other meaningful
goals.
7. I convince myself that I have
other meaningful goals to
pursue.

1

2

3

4

5

1

2

3

4

5

8. I tell myself that I have a
number of other new goals to
draw on.

1

2

3

4

5

9. I start working on other new
goals.

1

2

3

4

5

10. I put effort toward other
meaningful goals.

1

2

3

4

5

Section C: Physician-Patient Relationship
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Instructions: Please read each statement and decide how much you
disagree or agree with it. Circle one number for each statement and
answer in response to your view on your primary oncologist.
Primary Oncologist
Strongly
disagree
1

2

3

4

Strongly
agree
5

2. My doctor is extremely
thorough and careful.

1

2

3

4

5

3. Sometimes my doctor cares
more about what is convenient
for him/her than about my
medical needs.

1

2

3

4

5

4. My doctor is totally honest
with me.

1

2

3

4

5

5. All in all, I have complete
trust in this doctor.

1

2

3

4

5

1. I completely trust my
doctor’s decisions about which
treatments are best for me.

Patient Perception in Communication with Physician
Think about your recent contact with your primary oncologist. Then answer the
following questions by circling the number that best describes how you feel about
your recent contact with that person.

1. I understand the
possible side effects
of treatment.
2. If my doctor tells
me something that is
different from what I
was told before, it is
difficult for me to ask

very
strongly
disagree

strongly
disagree

disagree

not
sure

agree

strongly
agree

very
strongly
agree

1

2

3

4

5

6

7

1

2

3

4

5

6

7
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about it in order to get
it straightened out.
very
strongly
disagree

strongly
disagree

disagree

not
sure

agree

strongly
agree

very
strongly
agree

3. He/she is warm
and caring toward me.

1

2

3

4

5

6

7

4. If I don’t
understand something
my doctor says, I have
difficulty asking for
more information.

1

2

3

4

5

6

7

5. My doctor told me
what he/she hopes the
treatment will do for
me.

1

2

3

4

5

6

7

6. My doctor makes
me feel comfortable
about discussing
personal or sensitive
issues.

1

2

3

5

6

7

7. It was hard for me
to tell my doctor
about new symptoms.
8. It is hard for me to
ask about how my
treatment is going.
9. My doctor really
respects me.
10. I understand
pretty well the
medical plan for
helping me.

1

2

1

2

1

2

1

2

3

3

3
3

4

4

5

6

7

4

5

6

7

4

5

6

7

4

5

6

7
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11. After talking to
my doctor, I have a
good idea of what
changes to expect in
my health over the
next weeks and
months.

1

2

3

4

5

6

7

12. When I talk to my
doctor, I sometimes
end up feeling
insulted.

1

2

3

4

5

6

7

13. I have difficulty
asking my doctor
questions.
14. The treatment
procedure was clearly
explained to me.
15. My doctor
doesn’t seem
interested in me as a
person.
Please rate how
much the physician
seemed to:

1

2

3

4

5

6

7

1

2

3

4

5

6

7

1

2

3

4

5

6

7

very
strongly
disagree

strongly
disagree

disagree

not
sure

agree

strongly
agree

very
strongly
agree

16. Involve you in
treatment decisions.

1

2

3

4

5

6

7

17. Give you a sense
of control of medical
care.
18. To ask you to
take some
responsibility for care.

1

2

3

4

5

6

7

1

2

3

4

5

6

7

Neutral

Agree

Patient Perception of Primary Oncologist
Strongly
disagree

Disagree

Strongly
agree
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1. My doctor wants to know
about my nationality.
2. My doctor wants to know
about my racial background.

1

2

3

4

5

1

2

3

4

5

3. My doctor wants to know
about my religious practices
related to health issues.

1

2

3

4

5

4. My doctor wants to know
about my cultural
background.

1

2

3

4

5

Strongly
disagree
1

Disagree

Neutral

Agree

2

3

4

Strongly
agree
5

6. My doctor asks me if I
would feel discomfort if the
doctor touches me during
physical exam.

1

2

3

4

5

7. My doctor wants to know
if time is a concern for me
with regard to health exam.

1

2

3

4

5

8. My doctor wants to know
if time is a concern for me
with regard to medical
treatment.

1

2

3

4

5

9. My doctor tries to
understand my feelings.

1

2

3

4

5

10. My doctor tries to
understand my emotions.

1

2

3

4

5

11. My doctor wants to
know my viewpoint on

1

2

3

4

5

5. My doctor asks me who
makes important decisions
in my family.
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illness.
12. My doctor wants to
know my viewpoint on
treatment goals.

1

2

3

4

5
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Thank you!
TIME END: __________
Please estimate how long it took you to complete this questionnaire: _____ minutes
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APPENDIX B: DAILY DIARY ASSESSMENT QUESTIONS

ID: __________
DATE:__________
Daily Diary Assessment Questions rev. 2/8/2015

START TIME:

A. Mood
1. How much did you feel this way during the past day?
not at all
0

a little
1

moderately
2

quite a bit
3

extremely
4

anxious

0

1

2

3

4

quiet

0

1

2

3

4

sad

0

1

2

3

4

happy

0

1

2

3

4

relaxed

0

1

2

3

4

depressed

0

1

2

3

4

bored

0

1

2

3

4

nervous

0

1

2

3

4

peppy

0

1

2

3

4

angry

0

1

2

3

4

stimulated

0

1

2

3

4

cheerful

0

1

2

3

4

active
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energetic

0

1

2

3

4

guilty

0

1

2

3

4

lonely

0

1

2

3

4

2. How supportive were your interactions with your oncology team
today?
0
not at all

1

2

3

4
extremely supportive

5 = I did not have contact with my oncology team today
3. How difficult was chemotherapy today?
0
1
2
3
not at all
a little
somewhat moderately
applicable
4. How difficult was radiation today?
0
1
2
3
not at all
a little
somewhat moderately
applicable

4
very

4
very

5
not

5
not

5. Did you have any cancer setbacks today that required you to schedule
an appointment with your oncology team or healthcare provider? (e.g.
bad reaction to medication, loss of feeling in a limb)
yes

no

B. Stress & Relationships

1. How stressful were
your interpersonal

not
at
all
0

a
little
1

moderately extremely N/A or
no
contact
2
3
4
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interactions with people
who are important to you
today?
2. How enjoyable were
your interpersonal
interactions with people
who are important to you
today?

0

1

2

3

4

Experiences with Lung Cancer: Remember, respond to how much you
agree or disagree with these statements today.
strongly
strongly
disagree
agree
(1)
2
3
(4)
TODAY
I feel set apart, isolated from the rest
1
2
3
4
of the world.
Some people act as though it is my
1
2
3
4
fault that I have lung cancer.
Some people who know have grown
more distant.
I feel guilty because I have lung
cancer.

1

2

3

4

1

2

3

4

Having lung cancer makes me feel like
I’m a bad person.

1

2

3

4

C. Physical Symptoms
Please indicate the extent to which you experienced these symptoms or
problems during the past 24 hours.
Not at
all

a little
bit

quite a
bit

very
much

1. How much did you cough?

1

2

3

4

2. Were you short of breath?

1

2

3

4

3. Did you have pain?

1

2

3

4
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4. Did you feel weak?

1

2

3

4

5. Did you lack appetite?

1

2

3

4

6. Did you feel nauseated?

1

2

3

4

7. Did you have trouble sleeping?
(during the night)
8. Were you tired?

1

2

3

4

1

2

3

4

9. How much did your symptoms
interfere with your sleep?
10. How satisfied are you with the
quality of your sleep last night?

1

2

3

4

1

2

3

4

D. Functioning
The following questions ask you about the potential impact that lung
cancer may have had on your life today.

1. Did you need to stay in bed
or a chair during the day?

Not at
all

a little

quite a
bit

very much

1

2

3

4

2. Were you limited in doing
1
2
3
4
either your work or other daily
activities?
3. Were you limited in pursuing
1
2
3
4
your hobbies or other leisure
time activities?
4. Has your physical condition
1
2
3
4
or medical treatment interfered
with your family life today?
5. Has your physical condition
1
2
3
4
or medical treatment interfered
with your social life today?
Remember, respond to items for how true these statements are for you
today.
TODAY…
not a little somewhat quite very
at all
bit
a bit much
I am bothered by the side
0
1
2
3
4
effects of treatment
Because of my physical
0
1
2
3
4
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condition, I had trouble
meeting the needs of my
family today.
I feel useful.

0

1

2

3

4

I feel independent.

0

1

2

3

4

I feel like a burden to my
family.

0

1

2

3

4

I feel that my family
appreciates me.
I maintain contact with my
friends.

0

1

2

3

4

0

1

2

3

4

I make each day count.

0

1

2

3

4

0

1

2

3

4

0

1

2

3

4

I am able to openly discuss my
concerns with the people
closest to me.
I am able to enjoy life.

1. At the present time, I
am trying to pursue my
personal goals and plans.

1

2

3

4

5

2. There are ways around any
problem that I am facing now.

1

2

3

4

5

3. I can think of many ways to
reach my current goals.

1

2

3

4

5

6

6

6

definitely
TRUE

somewhat
true
mostly true

slightly
false
slightly true

somewhat
false

mostly false

definitely
FALSE

F. Use the following scale to rate these statements about today.

7

7

7

8

8

8
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4. At this time, I am
meeting the goals that I
have set for myself.
5. I am focused on what
matters to me as I go
through what I am facing
now.
6. I see many ways of
pursuing what is most
important to me now
7. Even though I may not
be able to meet a goal I
have set for myself, I am
doing what I can

1

2

3

4

5

6

7

8

1

2

3

4

5

6

7

8

1

2

3

4

5

6

7

8

1

2

3

4

5

6

7

8

8. Because it makes my
life better, it is important
for me to pursue what
may be possible for me
even if it is difficult

1

2

3

4

5

6

7

8

9. I see potential when I
think of what is ahead.

1

2

3

4

5

6

7

8

END TIME:

OR, estimate of how long this
took you today:

Optional: please feel free to tell us anything else that is important in
understanding how lung cancer affected your daily quality of life today.
This is completely optional.
____________________________________________________________
Please ensure that you have dated the questionnaire and provided an estimation of how
many minutes it took you to complete today if you did not write down the start and end
time.
Thank you! Each day you complete is a substantial contribution to this project’s larger
effort to establish quality of life research in lung cancer and identify potential ways to
help lung cancer patients.
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APPENDIX C: Participant Qualitative Responses
Theme
Interactions with
Medical Team

Quotes from Patients
The appointment yesterday was overwhelming with the oncologist. I
missed much of what was said, and I didn't understand what my
MRI results meant.
The blood transfusion nurse was very kind. It makes day-to day
things and appointments easier when people are kind.
Radiation doctor is great and helpful. I am glad he is back. The last
radiation doctor didn't seem interested in me as a person. This
doctor does.
I will be forever thankful for the two doctors who came my way and
took me to their care and to where I am now. I owe my life to them.
I could not have better care from such professional doctors. I've had
nothing but excellent care from everyone.
I had a difficult day at chemo. My IV had to be removed. The nurse
did not put the heprarin in and they could not get the IV to work.
After three tries yesterday it had to be removed. The nurse said she
would call the rapid response team to have them put in a new IV.
Another nurse came over and said are you ready. I told her no and to
call the rapid response team. She kinda got upset but I didn't care
since I didn't want unnecessary pokes at my body. The rapid
response team member did an excellent job and I hope this will last
til the end of the week so I don't have to go through it again this
week.
I had a terrible experience with chemo today. They were running
late as usual. When I finally got put into a station, the nurse forgot
about me and didn't even apologize. She said she was looking for
me but couldn't find me. I was put in the chair awaiting my
treatment, how could she not find me. She proceeded to tell me the
medications were running late because the lab was training in new
help. I suspect the drugs were late because she did not order them
cause she couldn't find me. I was not treated with dignity and
respect today. I do like the clinic but I am getting concerned with
the patient care.
I had lab work and my WBC shot today. The young lab tech said I
did not need lab work and nothing was in the computer. I assured
her to call the doctor because they always check my blood levels
once I finish chemo. The other nurse or lab tech came in and took
the blood work. She said this was a duplicate set of orders. I am
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getting tired of the poor treatment I am receiving. I have to keep
going but I get angry with the staff for not knowing and doing their
job.
the oncology people are incredible--they're a great bunch of people
Today was a very long day for me. Started with labs at 7am, then
back for more doctor visit and chemo. My chemo appointment was
set for 12 noon. We got started over 1 and a half hours later. Very
frustrating. I am discovering that having cancer and doing what's
needed is very hard work!
Symptoms

Tired and no appetite
So tired and walking is difficult wobble
SO TIRED
I am in treatment I can't do much of anything asking me if I am set
on goals is silly I a set on getting up and making it through the day.
I throw up, can't go to the bathroom and can hardly stay awake.
I am afraid I hope I get better than I am I am having trouble with
walking and catching my breath hasn't gone away I am weak. I
need more energy!
I have a cough, can't walk a lot as I get so winded. I did not have
this before, it hurts to cough and take deep breaths.
Breathing seems easier.
I was very anxious and nauseous today I am exhausted.
Cancer symptoms came on hard. In horrible pain for the last
month...some pain management was finally approved yesterday- big
difference for me not to have ups and downs
Nasty flu or whatever!
I just slept all day yesterday - not sure why Also have been losing
weight.
Feeling better after a rough week.
Today was a hard day for me. Felt like I had monkeys on my back.
Had to take a pain pill. Slept fairly well, but work up tired and weak
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for some reason.

Treatment
Delay/Progress

stressful day, feeling too tired to cope Will restart chem and radiaiton hopefully after today's appointment.
Physically and mentally, not appropriate for treatment last week.
This week, some improvement, but many complications and E.D.
visits have happened.
I do not feel good at all I am vomiting, have disagreed, sleep all of
the time. I am certain it is because I am on treatment.
I hope hope hope that I do well with this next round of
chemotherapy. I've tried to build myself up with acupuncture and
herbs
Hope my platelet count is OK - it was very, very low.
Today was "life interrupted". My partner was taken to hospital with
an intestinal bug. I was feeling ill like I did with the high calcium in
June so I called oncology to ask for a blood count. I was called
back later to come in for treatment to lower the calcium level. I also
have a low red cell count so I go back tomorrow for transfusion.
My house is a disaster!
Another day at Oncology for a red cell transfusion. We ran out of
time to get all complete yesterday.
Feeling pretty well. But less than a week and I start the whole
process again
First treatment went well
Not so good today - ended up this morning in er with blood clots.
Probably why have been feeling rotten the last few days/weeks.
start radiation tomorrow
radiation and chemotherapy tomorrow; long day ahead
Bad day + 1 more chemo tomorrow & 3 more radiations after today.
Yay!
yesterday was radiation & chemo - so I spent the day at the cancer
center, mostly in some chair/bed or another!
yesterday was a very long day = radiation, doctor & chemo so more
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difficult than others. also going on the downslope to finish
treatments & have some anxiety about that.
went to hospital last night. breathing problems
in hospital
hospital
hospital
hospital
still in hospital; tests and pain
hospital
still in hospital; dealing with meds and options
discharged; out of hospital
out of hospital but sore back and side weak
surgery tomorrow
blood transfusion yesterday--really helped me
Went to my oncology Dr's assistant today. She had good news
concerning improvement in my chemo treatment progress--which
was pretty much important
rough day. radiation twice today. good news is son-in-law will help
with afternoon radiation soon though--takes pressure off my spouse
been a good day; radiation machine was down this morning
radiation at 7 am; saw radiation doctor after that who said chemo
seemed to be working--cancer appears smaller!
I'm hopeful my IV lasts through the week (this round of chemo);
called my surgeon about my pain and got an appt with the surgeon
tomorrow morning
tumor continues to shrink
Radiation was quick and easy.
Today was a very long day. I had radiation then51/2 hours of
chemo. It was a long, tiring day buy worth it! I know I can beat
this!
Thanks to God and from Grace received from Jesus Christ through
working of the Holy Spirit I have received a letter from my doctor
saying that my condition is improving and chemo therapy is
working.
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The doctor sent me a letter and a graft showing chemo therapy is
working. Today is the day I have felt the best health-wise since I
started treatments
I am lucky they discovered this and I'm certain I can beat it!
I wake up everyday with a positive attitude and just know that I'm
gonna beat this cancer!
I remain positive on a daily basis! I am halfway through this
treatment and have high hopes that it is working!
Treatment side
effects

the side effects of my chemo were awful
side effects were awful and even though it has been a couple of
weeks,
the effects have not gone away
I experienced some side effects today, namely nose bleeds. Gotta
watch that.
I am tethered to oxygen 24/7, and house bound due to immune
compromise. It's hard to answer some of the questions at this stage.
My partner has been having issues with skin breakdown on her foot
(Type II). Dr. put her 2 antibiotics to speed up the healing. I've
been very careful not to share or have contact with anything she
uses. Today she had bad diarrhea, which kept me in a limited area
of the house. Scared me about contaminants.
A lot of the cough is allergy, I'm sure. New side effect - bruising
from the least little bump. Platelet infusion scheduled for tomorrow.
Steroids required for chemo kept me up and somewhat anxious most
of the night. This side effect is quite frustrating.
Steroids make me quite anxious and make sleeping problematic. On
the other hand, they provide more energy. I will be off them after
tonight.
Yesterday was last day of steroids.
First day of the more distressing side effects of the chemo
Difficult day due to chemo side effects and other external stressors
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Side effects of weakness and emotional fragility decreasing. I
should now have about 11 pretty good days until I start the cycle
over
had to have my hair on my head shaved off. This is the second time
for this. last time was about 2 years ago. It was not as traumatic as it
was before. I still did cry but said to myself "hey, I can rock a bald
head" lol
It would be good to suggest that individuals on long-term chemo
keep a journal of treatments, side effects, etc. It all starts blending
together and it is hard to remember whether worrying physical
symptoms could be drug side effects or new cancer symptoms.
I don't like staying home because I get bored. Having to carry
daytime O2 is a new burden ordered in June and it really impedes
leaving the house. Coughing has improved to just a short spasm in
the early morning hours. I work at deep breathing all day.
Since I don't feel ill, I have a hard time not being out with my
friends.
Chemo has taken every ounce of energy
I’ve been in treatment prior and know that chemotherapy was the
most difficult, took at least one week just to get up and the second
week to start feeling good again. It's just about the same right now,
the first week is extremely rough, second is just getting there I
should be much better by the end of this week.
My goals were to stop vomiting, hold water down! Pretty basic.
feel like I'm going to barf; 6 hour chemo and radiation today
Pretty good day - still feeling steroids from Tuesday chemo so more
energy, etc.
More pain & side effects influenced attitude & answers
diarrhea
hands and feet still hurting a lot--numb, feel frozen (side effect of
chemo); have a hard time picking stuff up like my pills
This is my 4th week of radiation and I am starting to feel tired and a
little weak.
I went to the Radiology Center yesterday and had an MRI with
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contrast that is probably why I felt nauseated today.
cold sweats most of the day
dry heaves, diarrhea, temperature, eyes wept, throat is raw, coughed
all through the night; if someone was older, I don't think I'd
recommend chemo and radiation--it is so hard
Yesterday was a rough day as I was nauseated and threw up and was
very tired all day.
radiation after effects are really tough
6 episodes of diarrhea today because of radiation. very exhausted;
two long days
radiation--my skin is dry and my throat is raw
second worst day I've had--diarrhea every 2 hours (7 attacks),
nauseated; thank God for the pills
I had acid reflux last night which caused me not to feel so good,
however, I feel better today!
I am reacting well to my treatment. No sickness or hair loss yet.
Doctors and physician assistants should tell their patients who wear
a tube in their stomachs to wear loose clothing around their tube
area to avoid pain. I learned this the hard way. I was wearing a belt
which I did not realize was putting pressure on my patch area and
causing pain which I thought was coming from my recent chemo
treatment.
I am getting a pain on upper and lower back. Also from my port area
where the hose is mounted for when we have to drain my lungs from
excessive water. Doctor said to drain every day for 3 days- then
resume prior schedule of every 3 or 4 days. First drain produce full
bag. Due to empty this afternoon about 7pm.
Today and yesterday were not good. I had a stomach ache. It is after
2pm and now I feel better.
Did not feel well today. Stomach upset.
I am wearing a port on my right side of my body. My wife uses it to
drain fluid from my lungs every 3 or 4 days--especially if I am
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going to get chemo treatment the next day. The port being there has
a bearing on some of the questions concerning my physical activity.
Anxiety/Fear

Anxious on my 2nd chemo treatments
I an exhausted, My sister will be going home one week from today.
I am scared.
I guess I am a little worried, I just don't seem to bounce back as
quickly this time around, I am sure four years makes a difference. I
am hopeful I will get through this.
I am so tired I know if I want to do something, I plan to do one or
two things and then I'm out of energy. I worry if my treatment will
work, I am worried about how I will handle anymore. It just seems
like it is taking much more out of me than four years ago. I
definitely feel this round of chemo.
I worry a lot about whether or not treatment will work how much
time do I have, making sure each day counts.
Again I worry, this is a totally different experience, my symptoms
are so different. I am not feeling so great and my next chemo is
Monday. The first time around, by the time I had chemo I was
much stronger.
Cough is somewhat worse the past few days. I hope it is just
allergies!
As I only have 2 more weeks of treatment left I am starting to get
anxious of the outcome. In my heart and mind I feel I will beat this
disease and live a lot longer! That is my hope!

Activities

Finally a better day was up and around lot of diapers but
manageable went outside was the best day so far
Each day I get stronger and able to do more.
I am getting stronger every day.
I spent today at home cleaning house as I was physically able.
Pretty sure I stirred up some dust but most rooms seem better. Now
I'm tired.
My partner is in hospital and may be sent to rehab for follow-up.
My son arrives tomorrow. My last chore is to make up his bed. I've
had mucho back pain from my scoliosis.
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Had a pleasant active day
Did a lot the last few days. Very tired today.
yesterday I ran a lot of errands with my sister. was very tired from
it, but it was a good day
I felt very motivated today and did chores with my family. I had a
good day today!
Today I did a load of laundry, dishes, we went for groceries and had
an early dinner with some good friends. One of my best days since
being "sick".
Had a great weekend and I've been feeling good and I'm prepared
for these next 3 weeks of treatment! My husband and I even went to
a movie yesterday afternoon!
Today was another good day as I am feeling good! I had a visit from
a co-worker today which was very nice!
It was a wonderful day today. A great get together with my family,
especially my 5 great grandkids. I'm doing great!
I look at my cancer as looking at life in a different light. I seem to
enjoy certain things more- like family and friends. I don't seem to
focus on my cancer too much. I know it's there but I don't linger on
the thought. I focus more on family- graduations- reunions, and
such.
had a good time with daughter last night--good food from church; in
touch with my family
family Thanksgiving was unreal--lots of blessings and
encouragement
another wonderful day
This has been a good day. Had fun with my sweetie and still in a
good mood.
Good day- Lots of laughter
Was able to do work my usual circle in my pasture only once--felt
weak and came in house to fill out this form
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Impact on Others

used to being healthy and active. walk dog, cook, clean, move freely
without pain.
husband was acting like this is my fault
used to being healthy and active. walk dog, cook, clean, move freely
without pain. not have to ask husband to help or else do it all for me
today. feel like a real burden to him. thankful he is a patient loving
man
husband is sick; argument (tension with husband)
My family is taking care of me. I am not taking care of them.
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Figure 1.
Participant Recruitment and Retention
62 eligible patients approached

56 consented (90.3%)

Completed both baseline and at least
1 daily diaries (n = 52; 92.9%)

Analyzed (n=50 people; 96.2%; 1051
days of data)

Refused (n = 6; 9.7%)
 “Busy with work” (n = 2)
 “sounds too tedious” (n = 1)
 “next 21 days are too uncertain” (n
= 1)
 “in too much pain” (n = 1)
 “concerns about limits of privacy
clause in consent (n = 1)

Withdrew after baseline (Completed 0
diaries) (n=4; 7.1%)
 “Busy schedule” (n = 1)
 Death (n = 1)
 Hospitalized for 1 week or more
(n=1)
 “Too much to handle right now”
(n = 1)

Excluded from analysis (n=2; 3.8%) as
did not have at least 7 days of
data
 Hospitalized for 1 week or more
(n = 1)
 Too much to handle right now”
(n = 1)
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Figure 2.
Average Number of Minutes per Day to Complete Each Diary in the Retained Sample (N
= 50)
16
14
12

Minutes

10
8
6
4
2
0
1

2

3

4

5

6

7

8

9

10 11 12 13 14 15 16 17 18 19 20 21

Day of Diary
Mean minutes

SD

92

Figure 3.
Frequency of “Quite a bit” or “Very much” Symptom Severity Endorsement across 21Day Diary
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Figure 4.
Interaction between Treatment Day and Daily Hope on Daily Social/Role Functioning
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Table 1
Descriptive Statistics of Sample

Study Variable

Overall Sample Consented
(n = 56)
Mean (SD)
% (n)

Sample Retained*
(n = 50)
Mean (SD)
% (n)

Age (years)

68.29 (9.47)

68.66 (8.78)

Sex
Female

57.1 (32)

58.0 (29)

Hispanic

14.3 (8)

16.0 (8)

non-Hispanic

82.1 (46)

80.0 (40)

3.6 (2)

4.0 (2)

82.1 (46)

80.0 (40)

African American

3.6 (2)

4.0 (2)

Native American

5.4 (3)

6.0 (3)

Asian/Pacific Islander

3.6 (2)

4.0 (2)

Other

1.98(1)

2.0 (1)

Missing (refused)

3.6 (2)

4.0 (2)

Ethnicity

Missing (refused)
Race
Caucasian

Highest Education (Years)

13.54 (2.73)

13.48 (2.04)

Annual Income ($)

43,671.85
(38,215.40)

38,662.91
(29,108.87)

Lung Cancer Subtype
Non-small cell

75.0 (42)

78.0 (39)

Small-cell

25.0 (14)

22.0 (11)

19.6 (11)

22.0 (11)

5.4 (3)

6.0 (3)

50.0 (28)

50.0 (25)

5.4 (3)

6.0 (3)

Lung Cancer Stage
IIIA NSLC
IIIB NSCLC
IV NSCLC
Limited (SCLC)
(Table continues)
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Table 1. Continued
Extensive (SCLC)

19.6 (11)

16.0 (8)

Chemotherapy

53.6 (30)

52.0 (26)

Chemoradiotherapy

32.1 (18)

32.0 (16)

8.9 (5)

10.0 (5)

1.8 (1)

2.0 (1)

Surgery and radiation

1.8 (1)

2.0 (1)

Surgery

1.8 (1)

2.0 (1)

Current Treatment

Radiation
Chemotherapy, radiation, and
surgery

Days since diagnosis

153.06
(202.88)

161.17
(209.47)

ECOG Performance Status
0

17.9 (10)

20.0 (10)

1

55.4 (31)

54.0 (27)

2

26.8 (15)

26.0 (13)

23.2 (13)

20.0 (10)

19.6 (11)

19.6 (9)

14.3 (8)

14.0 (7)

Brain Metastases
Yes
Whole Brain Radiotherapy
Yes
Current Smoking Status
Currently smoking
Pack Years

46.19 (39.43)

45.51 (40.06)

Marital Status
Married currently/living with
partner
(Table continues)

58.9 (33)

62.0 (31)
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Table 1 Continued

Note. ECOG = European Cooperative Oncology Group; Pack years = number of packs a day
divided by the number of years a person has smoked. *To be retained in the sample for daily
diary analysis, minimum number of days completed = 7.
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Table 2
Descriptive Statistics of Predictor Variables and Clinical Characteristics
Overall Sample Consented
Sample Retained*
(n = 56)
(n = 50)
Study Variable
Mean (SD)
% (n)
Mean (SD)
% (n)
Depression

5.48 (3.90)

> 8 (Probable depression)
Anxiety

5.34 (3.99)
33.9 (19)

5.57 (4.11)

> 8 (Probable anxiety)

34.0 (17)
5.22 (4.09)

32.1 (18)

28.0 (14)

FACT-G

74.83 (17.13)

75.04 (17.27)

TOI

52.05 (16.45)

52.20 (16.54)

FACT-L

92.11 (21.12)

92.45 (21.27)

Lung Cancer Scale (FACT)

17.59 (5.85)

17.77 (5.89)

Lung Cancer Stigma

47.21 (16.56)

45.22 (13.88)

Dyspnea (EORTC)

43.64 (36.22)

42.86 (36.64)

Fatigue (EORTC)

52.38 (27.36)

52.00 (28.26)

Nausea/Vomiting

13.69 (20.62)

12.33 (18.69)

Pain

34.24 (33.09)

33.67 (32.72)

Insomnia

35.71 (31.69)

34.00 (29.73)

Appetite Loss

32.74 (30.15)

30.67 (29.23)

Constipation

32.74 (36.23)

31.33 (35.89)

Diarrhea

13.10 (22.63)

14.00 (23.42)

Financial Difficulty

32.14 (37.04)

34.00 (37.79)

Physical Functioning

59.88 (22.97)

59.33 (22.79)

Role Functioning

53.27 (34.59)

53.33 (34.83)

Emotional Functioning

71.97 (23.71)

74.61 (22.48)

EORTC-QLQ-30 Symptom
Scales

EORTC-QLQ-30 Functional
Scales

(Table Continues)
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Table 2 Continued
Cognitive Functioning

72.62 (24.29)

73.00 (23.78)

Social Functioning

59.52 (29.28)

59.67 (29.37)

Hope (baseline)

25.71 (3.06)_

25.65 (3.03)

Neuroticism

16.98 (4.28)

16.72 (4.39)

Optimism

3.84 (0.72)

45.22 (13.88)

Note. *To be retained in the sample for daily diary analysis, minimum number of days
completed = 7.
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Table 3
Predictors of the Number of Days Completed in Diary
Study Variable
B (SE)

p

95% CI

Intercept
18.07 (4.36)
<.001
[9.32, 26.82]
ECOG performance status
-0.19 (1.35)
.888
[-2.90, 2.52]
Baseline quality of life
0.03 (0.05)
.514
[-0.07, 0.14]
Concurrent chemoradiotherapy
-0.27 (1.83)
.882
[-3.94, 3.40]
Diary administration method
-3.19 (1.84)
.089
[-3.94, 3.40]
Note. ECOG = European Cooperative Oncology Group (0-2); Baseline quality of life
measured by Functional Assessment of Cancer Therapy - General; concurrent
chemoradiotherapy received = 1; not received = 0; Daily administration method of paper (1)
or online/phone (0); Subtype (0 = small cell; 1 = non-small cell)
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Table 4
Average and Distribution of Functioning from Daily FACT-G Assessment and Lung
Cancer Symptoms in Daily Diary Sample
M
“Not at
“A
“Quite a “Very Missing
(SD)
all”
little”
Bit”
Much”
Scale Item
(n, %)
Did you need to stay in a
2.04
385
207
205
113
40
bed or chair?
(1.02) (36.6%) (29.2%) (19.5%) (10.8%) (3.8%)
Were you limited in either
doing your work or other
daily activities?

2.14
(0.92)

255
(24.3%)

463
(44.1%)

182
(17.3%)

106
(10.1%)

45
(4.3)

Were you limited in
pursuing your hobbies or
other leisure activities?

2.16
(0.97)

284
(27.0%)

402
(38.2%)

202
(19.2%)

122
(11.6%)

40
(3.8%)

Has your physical
condition or medical
treatment interfered with
your family life today?

1.68
(0.88)

551
(52.4%)

284
(27.0%)

116
(11.0%)

56
(5.3%)

44
(4.2%)

Has your physical
condition or medical
treatment interfered with
your social life today?

1.83
(0.99)

502
(47.8%)

277
(26.4%)

142
(13.5%)

93
(8.8%)

37
(3.5%)

How much did you
cough?

1.96
(0.79)

289
(27.5%)

521
(49.6%)

167
(15.9%)

41
(3.9%)

33
(3.1%)

Were you short of breath?

1.91
(0.89)

384
(36.5%)

411
(39.1%)

154
(14.7%)

69
(6.6%)

33
(3.1%)

Did you have pain?

1.87
(1.00)

487
(46.3%)

269
(25.6%)

167
(15.9%)

92
(8.8%)

36
(3.4%)

Did you feel weak?

2.26
(0.92)

202
(19.2%)

479
(45.6%)

206
(19.6%)

131
(12.5%)

33
(3.1%)

Did you lack appetite?

1.68
(0.92)

570
(54.2%)

261
(24.8%)

120
(11.4%)

65
(6.2%)

35
(3.3%)

Did you feel nauseated?

1.38
(0.78)

757
(72.0%)

161
(15.3%)

44
(4.2%)

47
(4.5%)

42
(4.0%)

Were you tired?

2.53
(0.90)

92
(8.8%)

473
(45.0%)

260
(24.7%)

188
(17.9%)

37
(3.5%)
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Table 5
Correlations between Study Variables in Diary Sample
1

2

3

4

5

6

7

8

9

10

11

12

13

14

15

16

Level 2
1. Hope
2. Stigma
3. Age
4. Tx type
5. Physical
Symptoms

-.41***
-.11***
-.04
-.07* .19***

-.02

-.36*** .41*** -.19*** .13***

6. Depression

-.44*** .40***

7. Anxiety

-.29*** .31*** -.16***

.01

.20***

.39***

.06+

.39***

.43***

Level 1
8. Days since
diagnosis
9. Hope
10. Stigma
11. Physical
Symptoms
12. Positive
affect
13. Negative
affect
14.Tx day

.16***

.13***

-.02

-.26***

.07*

.07*

.01

.00

.00

.00

.00

.00

.00

.00

-.01

.00

.00

.00

.00

.00

.00

.00

.00

-.02

.00

.00

.00

.00

.00

.00

.00

.00

-.20***

.23***

.00

.00

.00

.00

.00

.00

.00

.00

.29***

-.24***

-.52***

.00

.00

.00

.00

.00

.00

.00

.00

-.14***

.25***

.29***

-.38***

.06+

.07*

-.05+

.35***

-.05

-.04

-.13***

-.05

.01

-.02

-.02

.01

.06+

-.01

-.18*** -.59*** -.42***

-.43***

.00

.16***

-.12***

-.30***

.30***

-.16***

.00

.03

-.16*** -.37*** -.50***

-.27***

.02

.17***

-.09*

-.14***

.23***

-.10**

.02

.59***

-.04

-.24*** -.60*** -.48***

-.29***

-.05

.12***

-.08*

-.29***

.26***

-.14***

.00

.71***

15.Social/role
.51*** -.37***
functioning
16. Palliative
.59*** -.48***
well-being
17. Physical
.32*** -.24***
functioning
(Table Continues)

.40***
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Table 5 Continued
Note. Tx type = Treatment type (0 = not concurrent chemoradiotherapy; 1 = concurrent chemoradiotherapy); Tx day =
Treatment day (0 = not a treatment day; 1 = treatment day).
Level-2 variables: (Age was grand mean centered; Depression and anxiety were centered on value of “8” to indicate clinical
caseness; Other level-2 variables were person averages on the diary). Level-1 variables: Days since diagnosis was continuous
(i.e., day +1, day + 2, etc.); Predictor variables were person-mean centered (i.e., score – person mean); Dependent level-1
variables not person-mean centered.
***Significant at .001 level, **Significant at the .01 level, *Significant at the .05 level., + = p <.10
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Table 6
Predictors of Daily Functioning (role and social)
95% CI
Study Variable

Estimate (SE)

p

LL

UL

Fixed Effects
Intercept
65.00 (8.29)
<.001
48.76
81.25
Days since diagnosis
-0.01 (0.01)
.588
-0.02
0.01
Treatment day
-1.03 (1.04)
.322
-3.08
1.01
Daily hope
2.36 (0.70)
.001
1.00
3.73
Daily stigma
-3.64 (1.60)
.023
-6.78
-0.51
Daily positive affect
8.31 (0.95)
<.001
6.45
10.17
Daily negative affect
-1.87 (1.42)
.189
-4.65
0.92
Daily hope X treatment day
3.33 (1.25)
.008
0.88
5.77
Daily physical symptoms
-17.37 (2.63)
<.001
-22.52
-12.22
Average hope
5.06 (1.37)
<.001
2.37
7.75
Average stigma
-1.43 (4.57)
.755
-13.19
7.52
Age
-0.24 (0.22)
.293
-0.61
0.18
Treatment type
-4.04 (3.89)
.299
-11.66
2.35
Average physical symptoms
-21.66 (3.85)
<.001
-29.22
-14.11
Baseline anxiety
-1.22 (0.48)
.010
-2.16
-0.29
Random Effects
Residual (Level 2 intercept
136.60 (6.77)
73.52
183.48
variance)
Intercept variance
128.50 (28.05)
48.76
82.25
Intercept-Slope covariance
-3.58 (30.21)
-62.79
55.63
Slope
138.45 (58.76)
23.29
253.61
Note. Treatment type (1 = concurrent chemoradiotherapy; 0 = not in chemoradiotherapy); LL =
lower limit; UL = upper limit; SE = standard error.
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Table 7
Predictors of Next Day Daily Functioning (role and social)
95% CI
Study Variable

Estimate (SE)

p

LL

UL

Fixed Effects
Intercept
42.43 (13.56)
.002
30.14
53.91
Days since diagnosis
-0.001 (0.01)
.812
-0.01
0.01
Treatment day
-0.71 (1.27)
.576
-3.20
1.78
Daily hope
1.29 (0.73)
.078
-0.14
2.72
Daily stigma
-2.83 (1.93)
.141
-6.61
0.94
Daily positive affect
0.71 (1.23)
.564
-1.70
3.11
Daily negative affect
1.02 (1.73)
.554
-2.37
4.41
Daily functioning
0.35 (0.05)
<.001
0.26
0.44
Daily physical symptoms
-7.71 (2.68)
.004
-12.96
-2.45
Average hope
3.37 (0.90)
<.001
1.60
5.14
Average stigma
-1.86 (3.06)
0.543
-7.85
4.43
Age
-0.17 (0.13)
.184
-0.42
0.08
Treatment type
-2.78 (2.46)
.259
-7.60
2.04
Average physical symptoms
-13.91 (2.68)
<.001
-19.17
-8.66
Baseline anxiety
-0.72 (0.30)
.017
-1.32
-0.13
Random Effects
Residual (Level 2 intercept
194.09 (10.08)
174.34
213.85
variance)
Intercept variance
42.43 (13.56)
30.14
53.91
Intercept-Slope covariance
10.18 (19.35)
-27.75
48.11
Slope
60.51 (35.58)
-9.23
130.25
Note. Treatment type (1 = concurrent chemoradiotherapy; 0 = not in chemoradiotherapy); LL =
lower limit; UL = upper limit; SE = standard error.
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Table 8
Predictors of Physical Functioning
95% CI
Study Variable

Estimate (SE)

p

LL

UL

Fixed Effects
Intercept
85.47 (10.33)
<.001
65.22
105.72
Days since diagnosis
-0.01 (0.01)
.280
-0.04
0.01
Treatment day
-0.08 (1.44)
0.957
-2.90
2.74
Daily hope
2.27 (0.81)
.005
0.68
3.87
Daily stigma
1.15 (2.20)
.600
-3.16
5.47
Daily positive affect
8.64 (1.31)
<.001
6.08
11.19
Daily negative affect
-1.57 (1.96)
.422
-5.41
2.26
Daily physical symptoms
-26.11 (3.67)
<.001
-33.30
-18.92
Average hope
1.48 (1.81)
.323
-1.75
5.32
Average stigma
8.28 (5.79)
.152
-3.06
19.63
Age
-0.56 (0.26)
.034
-1.08
-0.04
Treatment type
-10.11 (4.95)
.041
-19.81
-0.41
Average physical symptoms
-32.06 (4.83)
<.001
-41.52
-22.60
Baseline depression
-1.78 (0.67)
.008
-3.10
-0.46
Random Effects
Residual (Level 2 intercept
259.42 (12.85)
234.24
284.61
variance)
Intercept variance
215.30 (47.44)
122.31
308.28
Intercept-Slope covariance
-77.48 (58.28)
-191.70
36.74
Slope
282.59 (104.57)
77.62
487.55
Note. Treatment type (1 = concurrent chemoradiotherapy; 0 = not in chemoradiotherapy); LL =
lower limit; UL = upper limit; SE = standard error.
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Table 9
Predictors of Next Day Physical Functioning
95% CI
Study Variable

Estimate (SE)

p

LL

UL

Fixed Effects
Intercept
62.35 (8.95)
<.001
44.80
79.89
Days since diagnosis
-0.01 (0.01)
.399
-0.03
0.01
Treatment day
0.39 (1.75)
.822
-3.04
3.83
Daily hope
-0.70 (0.98)
.473
-2.62
1.22
Daily stigma
-2.21 (2.61)
.397
-7.32
2.90
Daily positive affect
0.30 (1.63)
.852
-2.89
3.49
Daily negative affect
4.01 (2.35)
.089
-0.61
8.62
Daily functioning
0.27 (0.05)
<.001
0.18
0.36
Daily physical symptoms
-12.16 (3.58)
<.001
-19.14
-5.12
Average hope
1.18 (1.40)
.398
-1.56
3.92
Average stigma
5.93 (4.39)
.177
-2.67
14.53
Age
-0.45 (0.20)
.025
-0.85
-0.06
Treatment type
-7.39 (3.88)
.057
-15.00
0.21
Average physical symptoms
-23.68 (4.10)
<.001
-31.71
-15.64
Baseline depression
-1.49 (0.52)
.004
-2.50
-0.48
Random Effects
Residual (Level 2 intercept
362.68 (18.87)
325.69
399.67
variance)
Intercept variance
105.35 (30.31)
45.93
164.77
Intercept-Slope covariance
-38.85 (39.84)
-116.93
39.23
Slope
91.20 (61.74)
-29.81
212.22
Note. Treatment type (1 = concurrent chemoradiotherapy; 0 = not in chemoradiotherapy); LL =
lower limit; UL = upper limit; SE = standard error.
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Table 10
Predictors of Palliative Wellbeing
95% CI
Study Variable

Estimate (SE)

p

LL

UL

Fixed Effects
Intercept
16.19 (2.14)
<.001
12.00
20.38
Days since diagnosis
-0.001 (0.002)
.808
-0.01
0.004
Treatment day
-0.45 (0.22)
.041
-0.89
-0.02
Daily hope
0.91 (0.13)
<.001
0.66
1.16
Daily stigma
-0.80 (0.34)
.019
-1.46
-0.13
Daily positive affect
2.05 (0.20)
<.001
1.66
2.45
Daily negative affect
0.10 (0.30)
.737
-0.49
0.70
Daily physical symptoms
0.01 (0.53)
.984
-1.02
1.05
Average hope
1.54 (0.37)
<.001
0.81
2.26
Average stigma
-3.37 (1.20)
.005
-5.73
-1.01
Age
0.06 (0.05)
.236
-0.04
0.17
Treatment type
-0.53 (1.02)
.606
-2.52
1.47
Average physical symptoms
-0.99 (1.07)
.355
-3.10
1.11
Baseline anxiety
0.11 (0.13)
.390
-0.14
0.35
Baseline depression
-0.38 (0.15)
.009
-0.66
-0.09
Random Effects
Residual (Level 2 intercept
6.22 (0.31)
5.61
6.82
variance)
Intercept variance
9.34 (2.02)
5.37
13.30
Intercept-Slope covariance
2.47 (1.81)
-1.07
6.01
Slope
4.97 (2.20)
0.66
9.27
Note. Treatment type (1 = concurrent chemoradiotherapy; 0 = not in chemoradiotherapy); LL =
lower limit; UL = upper limit; SE = standard error.
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Table 11
Predictors of Next Day Palliative Wellbeing
95% CI
Study Variable

Estimate (SE)

p

LL

UL

Fixed Effects
Intercept
8.73 (1.45)
<.001
5.90
11.57
Days since diagnosis
0.00 (0.001)
.931
-0.003
0.003
Treatment day
-0.15 (0.25)
.544
-0.63
0.34
Daily hope
0.13 (0.14)
.379
-0.15
0.40
Daily stigma
-0.34 (0.37)
.361
-1.06
0.38
Daily positive affect
0.49 (0.24)
.037
0.03
0.96
Daily negative affect
0.29 (0.33)
.382
-0.36
0.94
Daily palliative wellbeing
0.46 (0.04)
<.001
0.38
0.55
Daily physical symptoms
0.34 (0.48)
.485
-0.61
1.28
Average hope
0.88 (0.24)
<.001
0.40
1.35
Average stigma
-1.71 (0.71)
.016
-3.10
-0.32
Age
0.03 (0.03)
.372
-0.03
0.09
Treatment type
-0.46 (0.60)
.440
-1.64
0.71
Average physical symptoms
-0.81 (0.60)
.175
-1.98
0.36
Baseline anxiety
0.06 (0.07)
.404
-0.08
0.20
Baseline depression
-0.16 (0.09)
.063
-0.33
0.01
Random Effects
Residual (Level 2 intercept
7.09 (0.37)
6.37
7.81
variance)
Intercept variance
2.70 (0.78)
1.17
4.22
Intercept-Slope covariance
0.24 (0.83)
-1.39
1.88
Slope
1.70 (1.20)
-0.65
4.06
Note. Treatment type (1 = concurrent chemoradiotherapy; 0 = not in chemoradiotherapy); LL =
lower limit; UL = upper limit; SE = standard error.
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Table 12
Predictors of Daily Hope
95% CI
Study Variable

Estimate (SE)

p

LL

UL

Fixed Effects
Intercept
-0.34 (1.23)
.784
-2.77
2.06
Days since diagnosis
0.001 (0.001)
.377
-0.001
0.002
Treatment day
0.02 (0.06)
.684
-0.09
0.14
Daily positive affect
0.10 (0.06)
.101
-0.02
0.20
Daily social/role functioning
0.01 (0.002)
<.001
0.004
0.01
Daily physical functioning
0.002 (0.001)
.171
-0.001
0.01
Daily palliative wellbeing
0.05 (0.01)
<.001
0.04
0.07
Daily physical symptoms
0.05 (0.17)
.779
-0.28
0.38
Age
-0.02 (0.02)
.375
-0.05
0.02
Treatment type
0.20 (0.32)
.525
-0.42
0.82
Average physical symptoms
0.17 (0.44)
.696
-0.70
1.04
Baseline depression
-0.03 (0.05)
.557
-0.13
0.07
Average social/role functioning
0.03 (0.01)
.039
0.001
0.05
Average physical functioning
-0.01 (0.01)
.642
-0.02
0.02
Average palliative wellbeing
0.14 (0.04)
.001
0.06
0.22
Random Effects
Residual (Level 2 intercept
0.42 (0.02)
0.38
0.46
variance)
Intercept variance
0.89 (0.20)
0.51
1.27
Intercept-Slope covariance
0.24 (0.16)
-0.08
0.55
Slope
0.67 (0.23)
0.22
1.13
Note. Treatment type (1 = concurrent chemoradiotherapy; 0 = not in chemoradiotherapy); LL =
lower limit; UL = upper limit; SE = standard error.
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Table 13
Predictors of Next Day Hope
95% CI
Study Variable

Estimate (SE)

p

LL

UL

Fixed Effects
Intercept
-0.45 (0.74)
.537
-1.87
0.99
Days since diagnosis
0.001 (0.00)
.027
0.000
0.002
Treatment day
-0.05 (0.06)
.419
-0.16
0.07
Daily positive affect
0.01 (0.05)
.910
-0.10
0.11
Daily social/role functioning
0.003 (0.002)
.114
-0.001
0.01
Daily physical functioning
-0.001 (0.001)
.601
-0.003
0.002
Daily palliative wellbeing
0.03 (0.01)
.003
0.01
0.04
Daily hope
0.43 (0.04)
<.001
0.36
0.50
Daily physical symptoms
0.13 (0.13)
.328
-0.14
0.36
Age
-0.01 (0.01)
.264
-0.03
0.01
Treatment type
0.22 (0.19)
.232
-0.14
0.59
Average physical symptoms
0.13 (0.27)
.627
-0.39
0.65
Baseline depression
-0.02 (0.03)
.459
-0.08
0.04
Average social/role functioning
0.01 (0.01)
.084
-0.002
0.03
Average physical functioning
0.000 (0.01)
.993
-0.01
0.01
Average palliative wellbeing
0.08 (0.03)
.001
0.03
0.13
Random Effects
Residual (Level 2 intercept
0.38 (0.02)
0.34
0.41
variance)
Intercept variance
0.29 (0.07)
0.14
0.43
Intercept-Slope covariance
0.04 (0.07)
-0.09
0.17
Slope
0.21 (0.12)
-0.02
0.44
Note. Treatment type (1 = concurrent chemoradiotherapy; 0 = not in chemoradiotherapy); LL =
lower limit; UL = upper limit; SE = standard error.

